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ABSTRACT
The extracellular matrix (ECM) includes the interstitial matrix and the basement 
membrane (BM). The BMs are specialized sheets of extracellular matrices found in contact 
with the epithelia, endothelia and certain individual cells. They function mainly to organize 
and support tissue architecture as barriers and filters and to regulate cell behaviour. Type IV 
collagen and laminins are the major networking components of the BM. Both these BM 
components are composed of different isoforms of the basic subunits, which confers 
structural and functional diversity to the BMs.  
The loose connective tissue, adipose tissue or fibrous tissue like synovial connective 
tissue is located within the synovial joints and is covered by the synovial lining layer, which 
together form the synovial membrane. Synovial lining layer is the innermost layer the 
synovial membrane, which faces the synovial cavity and synovial fluid. The synovial lining 
or intima lacks a BM but the major networking components of the BMs are found in the 
intracellular spaces in the lining layer. The synovial lining bears some superficial 
resemblance to epithelia but is composed of macrophage-like type A cells and fibroblast-like 
type B cells, which are cemented together by an intercellular matrix, which as mentioned 
seems to contains the major components of the BMs. Unlike the synovial lining, which lacks 
a BM, the salivary glands contains BM which surrounds the acini and the ducts composed of 
salivary gland epithelial cells. 
This thesis aimed to study the composition of two major components of the BM; type 
IV collagen and laminin 4 and 5 in the synovial lining (which contains BM components, 
which however are not organized to a BM) and the BM of the salivary gland and further 
compare the intercellular cementing matrix and epithelial BM in healthy conditions and in 
disease conditions. In parallel this thesis investigates the provisional matrix component of 
endothelial BMs, which is formed upon endothelial cell injury, namely von Willebrand factor 
(vWF). Such provisional matrix contains also other components, such as fibrinogen, 
thrombin, fibronectin and vitronectin. The presence of vWF is an indication of microvascular 
damage which might reflect the pathogenesis of the syndrome and could in part be 
responsible for impaired salivary flow in Sjögren’s syndrome (SS). 
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Rheumatoid arthritis (RA) is a female dominated disease and is characterized by 
chronic, systemic inflammatory disorder affecting especially joints, but also various other 
tissues and organs. It is thought to essentially affect the joints resulting in an inflammatory 
synovitis that has the potential to destroy the articular cartilage and subchondral bone of the 
joints. The main cause of RA is still elusive, but it is well known that autoimmunity plays a 
pivotal role in its chronic nature and promotes progression of the disease. Continuous 
inflammation leads to synovial hyperplasia and, further, in formation of pannus tissue. The 
patients characteristically have polyarticular and symmetrical joint swelling, stiffness and 
pain, which many a times cause functional disability. This inflammatory synovial membrane 
and villous hyperplasia of synovial lining, unlike the normal synovial lining, contains a 
compromised intracellular matrix composition. Our studies showed that certain  chains type 
IV collagen are low in RA compared to control synovial linings, while laminin 5 exhibited a 
pattern of low expression regions at the synovial lining interface towards the joint cavity and 
fluid. Also, high numbers of macrophage-like lining cells containing MMP-9 were found in 
the lining. MMP-9 was also found in the synovial fluid. This causes a considerable 
transmigration of neutrophils into the synovial fluid. Typically in RA patient the synovial 
fluid contains many inflammatory cells, mostly neutrophils, which transmigrate from the 
blood vessels of the synovial tissue to synovial fluid.  
Sjögren’s Syndrome (SS) is another systemic female dominated autoimmune disease, 
characterized by dry eyes (keratoconjunctivitis sicca) and dry mouth (xerostomia) as well as 
fatigue, Raynaud’s phenomenon and arthralgia. It may be primary but may also develop in 
the context of an underlying autoimmune rheumatic disease, like RA. Typically in 
histopathological sections of exocrine salivary glands abundant lymphocyte infiltrates, focal 
adenitisi, along with acinar cell atrophy and ductal cell hyperplasia are found. These findings 
are well characterized and have been known for long but the eventual role of BM for these 
changes is largely unclear. The BM of this tubuloacinar gland undergoes considerable 
changes with regards to its composition. Collagen 1/2 (IV) mRNA was found to be present 
in high amount compared to the other (IV) chains and also showed intense labelling in 
immunohistochemical staining in normal and SS patients and therefore is thought to forms 
the backbone of this tubuloacinar BM. Some collagen 3(IV) and 4(IV) mRNA was found 
in LSG explants and also in cultured human submandibular cell line, but was not translated to 
the corresponding  chain proteins in the LSG. In healthy glands 5(IV) and 6(IV) chains 
were found to be continuous around ducts but discontinuous around acini. Type IV collagen 
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5(IV)  and  6(IV)  mRNAs  were  present  in  LSG  explants  and  HSG  cell  line,  while  in  SS  
these chains seemed to be absent or appear only in patches around the ductal BM and tended 
to be absent around acini in immunohistochemical staining, indicating that their synthesis 
and/or degradation seemed to be locally regulated around acinar cells. Earlier studies from 
our group have shown that in SS laminin 1 and 2 chains are weakly present and laminin 4
was present in areas infiltrated by lymphocytes suggesting that laminin 1, 2, and 4 chains 
were associated with acinar cells, myoepithelial cells, and tissue damage/repair, respectively. 
The provisional matrix component vWF is an oligo- or multimeric interadhesive 
glycoprotein involved in stabilization of factor VIII and in hemostasis. It functions by 
forming bridges between subendothelial perivascular collagens (collagen-binding domains) 
and blood platelets (platelet glycoprotein-binding domain) promoting platelet adhesion to 
sites of vascular damage. Any focal damage to the microvasculature leads to release of von 
Willebrand factor from Weibel-Palade bodies in the endothelial cells and its reciprocal 
deposition in perivascular connective tissue. Thus, vWF serves as a marker of vascular 
damage. Microvasculature in SS showed signs of focal damage which in turn might impair 
arteriolar feeding, capillary transudation and venular drainage of blood. However, capillary 
density was not decreased but rather increased, perhaps as a result of angiogenesis 
compensatory to microvascular damage. Microvascular involvement of LSG may contribute 
to the pathogenesis of this syndrome. 
Thus,  in  this  thesis  we  explored  the   chain  composition  of  type  IV  collagen  and  
laminin 4 and laminin 5 of the synovial intercellular matrix in healthy controls and 
compare this data with the changes that may occur due to inflammatory tissue destruction 
and/or remodelling in RA. Secondly, we studied the type IV collagen composition of the 
tubuloacinar and the vWF content of the vascular BM of the labial salivary gland in healthy 
controls compared to patients with SS to check if similar changes occur in BMs in two 
different chronic autoimmune diseases. In case of RA the patient controls were from OA 
patients while in SS the controls were obtained from patients who were suspected but did not 
in the final evaluation have SS. In parallel, we investigated vascular endothelium for any 
signs  of  damage  in  SS  which  might  be  the  cause  of  diminished  salivary  flow  and  could  
contribute  to  the  pathogenesis  of  SS.  The  main  molecules  evaluated  in  this  thesis,  type  IV  
collagen, laminins and vWF, were studies at the protein and/or mRNA levels using 
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immunohistochemical staining and quantitative RT-PCR, the other key molecules were also 
studied using zymography.   
This thesis advances our understanding of the major BM components in two different 
tissues subjected to two different but somewhat related autoimmune disease processes at the 
molecular level. 
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REVIEW OF THE LITERATURE
THE EXTRACELLULAR MATRIX  
Overview
he  extracellular  matrix  (ECM)  was  once  thought  to  be  an  inert  scaffold  which  
functions mainly to stabilize the physical structure of the tissue, but now we know 
that it was just an underestimation. The ECM is ubiquitously found surrounding 
cells, cellular structures and organs and fills up the extracellular spaces. Each and every cell 
come in close contact with the ECM, either throughout or at important phases of the cells life, 
it can be either as stem or a progenitor cells or during cell migration and invasion (Hynes, 
2009). It is a dynamic structure which undergoes constant remodelling. The amount and 
molecular composition of the ECM are typical for each tissue and affect the form, physical 
properties,  and  function  of  the  tissue.  The  ECM  includes  the  interstitial  matrix  and  the  
basement membrane (BM) and plays a key role in the maintenance of the tissue architecture, 
continuity and forms filtering passageway barriers for macromolecules and cell trafficking. 
Additionally, it regulates cell behaviour via interactions with the cell surface receptors, 
thereby mediating effects of mechanical loading on cells/tissues and serves as a reservoir of 
growth factors including fibroblast growth factors (FGFs) and vascular endothelial growth 
factors  (VEGFs).  Mutations  in  the  genes  coding  constituents  of  the  ECM  underlie  several  
human diseases. 
The diversity of the ECM is achieved by the variations in the relative amount of the 
different types of matrix macromolecules. This diversity helps to attain the functional 
properties typical of each tissue. For example, the matrix can become calcified to form hard 
structures of bone and teeth, or form transparent matrix such as in cornea or can adopt a rope 
like organization seen in tendons giving them tensile strength whereas at the interface 
between the epithelia and connective tissue the matrix forms the BM with considerable 
T
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mechanical elastic resistance against lateral stretching. The ECM is far from being static and 
is known to constantly undergo remodelling and renewal by the breakdown by proteases 
coupled with resynthesis (Bosman and Stamenkovic, 2003). 
The components of the ECM are largely produced locally by cells in the matrix and 
belong to two main classes; polysaccharide chains of glycosaminoglycans (GAGs), which are 
usually found covalently linked to protein in proteoglycans, and fibrous proteins, including 
collagen, laminin, elastin and fibronectin (Aumailley and Gayraud, 1998). GAGs are 
polysaccharide chains which are unbranched and are composed of repeating disaccharide 
units. One of the repeating disaccharides is always an amino sugar (N-acetylglucosamine or 
N-acetylgalactosamine) which are mostly sulphated, while the second sugar is usually uronic 
acid. GAGs are grouped into major groups, namely hyaluronan, chondroitin sulphate, 
dermatan sulphate, keratan sulphate, heparan sulphate and heparin. This classification is 
based on their sugar constituents, the type of linkage between the component sugars and the 
number and location of the sulphate groups. An important property of GAGs is their strong 
hydrophilicity. They can bind large volumes of water relative to their molecular mass and 
form thus hydrated porous gel suitable for embedding of the fibrous components of the ECM 
and cells. The sulphate or carboxyl groups on most of the sugar make them the most anionic 
molecules produced by animal cells. This high density of the negative charge attracts cations 
(mostly Na+), that are active osmotically thus causing a suction of large amount of water. The 
resultant swelling pressure/turgor enables the matrix to withstand compressive forces. This 
way the matrix of the hyaline articular cartilage, which lines the gliding surfaces of the joints, 
can withstand some hundreds of bars of pressure Alexander (Alberts et al., 2004). 
Collagens are the major fibrous proteins of the ECM and at the same time the most 
abundant fibrous proteins found in humans. They are secreted by the connective tissue cells, 
as well as by a variety of other cell types. Their basic structure is a triple helix composed of 
chains wound around each other in a rope-like structure. They are rich in proline and glycine 
which are important for the formation of triple-stranded helix. Proline stabilises the helical 
conformation in each  chain owing to its ring structure while glycine spaces itself regularly 
at every third residue throughout the central region of the collagen helix. Depending upon the 
 chain composition there are at least 20 different types of collagens for which the functions 
are known but genes for already 28 different collagens have now been identified. An intricate 
association between the different collagen fibrils or networks provides the respective tissue 
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with their tensile strength apart from other biochemical collagen functions. The collagens 
interact specifically with their cell surface receptors thereby playing a role in the 
orchestration of various cell behaviours (Myllyharju and Kivirikko, 2004). There are several 
different classes of collagens such as: fibrillar collagens that occur in the connective tissue 
and usually contain abundantly collagen I, II, III, V, and XI, type I being the most common; 
fibril-associated collagens, such as collagen IX and XII found on the surface of the collagen 
fibrils and thought to link the fibrils to each other and to other ECM components as well as to 
regulate the thickness of the collagen fibers; and network-forming collagens like the type IV 
collagen, which forms a network; while type VII collagen molecules form dimers that 
assemble into specialized structures called anchoring fibrils. Detailed in the table below 
(Table 1). 
Class Type of Collagen 
Fibrillar I, II, III, V, XI, XXIV, XXVII, XXVIII 
3D network (basement membrane) IV
Microfibrils (beaded-filaments) VI
Anchoring fibrils VII 
Hexagonal lattice VIII, X 
Fibril Associated Collagens with 
Interrupted Triple helices (FACIT) 
IX, XII, XIV, XVI, XX, XXI 
FACIT-like XIX, XXII, XXVI 
Transmembrane XIII, XVII, XXIII, XXV 
Multiplexins XV, XVIII 
Table 1: Collagen types 
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Basement membrane components 
As mentioned above, BM and the interstitial matrix make up the ECM. The interstitial 
matrix is found in the intercellular tissue spaces as gels of non-collagenous polysaccharides, 
proteoglycans, glycoproteins and proteins, and the eonforcing fibrous collagenous proteins. 
This arrangement acts as a compression and expansion buffer against the stress placed on the 
ECM (Alberts et al., 2004). BMs are sheet-like interfacial depositions of ECM on which 
various cells rest. These specialized networks of ECM macromolecules surround the 
epithelial, endothelial, muscle, adipose and nerve cells. BM was first identified using light 
microscopy by Robert Todd and William Bowman in 1845 (Merker, 1994), while type IV 
collagen was first isolated from the glomerular BM by Kefalide (Kefalides, 1966). The BMs 
are always in contact with cells where they function to provide structural support, divide 
tissues into compartments and as well as regulate cell behaviour (Aumailley and Timpl, 1986; 
Paulsson, 1992). The BMs are largely composed of type IV collagen, laminins, heparin 
sulphate proteoglycans and nidogen/entactin. These components are large insoluble 
molecules that self assemble to form sheet-like structures. The association of several genetic 
and acquired diseases with defects in the BM components have been detected (Hudson et al., 
1993).  Evidence points out that the BM must be considered, not only as a supporting 
network for various cell types, but also as a potential regulator of cell behaviour (Tamamura 
et al., 2006). 
Type IV collagen 
Collagens type IV as mentioned above is a network forming collagen and constitute a 
major part of the BM and are responsible for its mechanical resistance (Kuhn, 1995). 
Collagen type IV was first identified by Kefalides in 1966 (Kefalides, 1966). Type IV 
collagen is in part synthesized by the adjacent parenchymal cells or by the epithelial or 
endothelial cells themselves (Bosman and Stamenkovic, 2003). The Type IV collagen 
consists of a family of six genetically distinct  chains designated 1-6. Three  chains 
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assemble into triple-helical collagen molecules that further self associate to form a 
supramolecular network. The 1(IV) and 2(IV) are the classical chains of type IV collagen 
and are widely 
distributed in most 
BMs, while the other 
four chains, ie. 3 (IV), 4(IV), 5(IV), 6(IV) 
chains (novel chains), have a more restricted 
distribution in the BM of selected organs. The classical type IV collagen maintains the cell 
phenotype mediated by the membrane receptor integrin 11 and integrin 21 (Aumailley 
and Timpl, 1986). Comparatively little is known about the biological implications of type IV 
collagen novel chains. Only few clues about their functions have been found from different 
human genetic diseases in which the gene encoding for a particular type IV collagen  chain 
subunit is mutated or deleted. For example mutation in the genes coding for 5(IV), 3(IV), 
and 4(IV) chains have been described in X-linked and autosomal forms of Alport syndrome 
(Tryggvason, 1996). 
Laminins 
Laminins are -heterotrimeric glycoproteins with 30 years long history 
(Miner, 2008). Until now five -, four - and three -chains are known and from them all so 
far known 16 laminin trimers are composed of in different combinations, always of one -,
one - and one - chain. It is highly probable that there exist even more trimer combinations 
yet to be revealed. The -, - and  -chains form a triple-helical coiled-coils linked by 
disulfide bridges. The laminin trimer types have several shapes including cruciform, T-, Y- or 
rod-shaped  forms.  The  short  arms  of  the  laminin  which  could  be  2  in  case  of  laminin  
containing 4 chain or 3 in rest of the laminin chains begin from the N-termini (also referred 
to as LN). The globular LN domain is followed by tandems of epidermal growth factor-like 
(LE) domains. The long arm of the laminin structure terminates at the C termini. At the centre 
of the cross all the three chains are bound together by disulphide bridges.  
Figure 1: A hetro trimeric type IV 
collagen chain consisting of  chains 
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The isoforms of laminin are synthesized by a wide variety of cells in a tissue-specific 
manner. Virtually all epithelial cells synthesize laminins, as do smooth, skeletal and cardiac 
muscle cells, nerves, endothelial cells, bone marrow cells and neuroretina. The synthesizing 
cells deposit laminins mostly but not exclusively in the BMs. It is well established that the 
laminins have a wide variety of effects on the adjacent cells which include cell adhesion, 
migration and differentiation. The effects are mostly exerted via integrins. The integrin 
binding specificity of the laminins is predominantly governed by the  chain (Colognato and 
Yurchenco, 2000; Hirosaki, 2000; Hynes, 1992; Ido et al., 2004).  
The primary role of laminins seem to be mediation of the interaction between cells 
and the ECM, including BM (Aumailley and Smyth, 1998). Consequent with the wide range 
of the roles played by laminins in tissue structure and cell function, they are considered to be 
significantly involved in disease processes. The role of laminin in tumour invasion and 
metastasis and in angiogenesis has been intensely studied. These studies have shown that the 
dysregulation of the interaction between cancer cells and the ECM is accompanied by 
aberrant synthesis, chain composition and proteolytic modification of laminins (Patarroyo et 
al., 2002). Viral infection or any incurrent infection that stimulates dendritic or other cells to 
activate the HLA-independent innate immune system could be an environmental trigger for 
inflammatory-autoimmune diseases e.g. via Toll-like receptors (Takeda et al., 2003). Possibly 
these changes lead to liberation of chemokines and upregulation of adhesive molecules that 
direct neutrophil, monocytes and lymphocyte migration into the diseased tissue. X-
chromosome-linked factors might influence apoptosis in patients with RA and SS 
(Nakamura, 2000). Sex steroids produced endocrine glands or in peripheral tissues in 
intracrine processes can also influence cell behaviour and may in part explain the dominance 
of females over males in most autoimmune diseases (Laine et al., 2007; Porola et al., 2008; 
Spaan et al., 2009). 
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Laminin 4 and 5 chains 
The human laminin 4 chain gene, denoted LAMA4, was discovered in 1994 
(Richards et al., 1994). Laminin 4 chain is a truncated laminin  chain with only three 
complete LE domains flanked by two incomplete LE 
domains in the N-terminus. The laminin 4 chain is a 
constituent of at least three laminin trimers, which are 
laminin-411, laminin-421 and laminin-423 previously 
designated as laminin-8, -9, and -14 respectively. The new 
identification system for the laminin trimers uses three 
Arabic numerals, based on ,  and  chain numbers 
(Aumailley et al., 2005). The T shape of the laminin 4 has 
been shown using rotary shadowing electron microscopy 
(Frieser et al., 1997; Kortesmaa et al., 2000). Apart from 
the truncation the laminin 4 is also unique in having 
chondroitin sulphate modification in the N-terminal short 
arm (Kortesmaa et al., 2002; Sasaki et al., 2001). Northern 
blotting of adult human tissues showed high laminin 4
chain mRNA expression in the heart, lung, skin, liver, 
ovary and placenta, but weak expression in intestine, pancreas, testis, prostate and skeletal 
muscles and negligibly expressed in the brain (Richards et al., 1996; Richards et al., 1994). 
The function of 4 chain is largely elusive. In vitro experiments suggest that human 
fibrosarcoma, glioblastoma, lymphoid cells and platelets adhere with variable affinities to 
laminin-411 (Fujiwara et al., 2001; Geberhiwot et al., 2001; Geberhiwot et al., 1999; 
Kortesmaa et al., 2002; Kortesmaa et al., 2000; Pedraza et al., 2000). Laminin-411 has been 
shown to promote migration of human glioma and lymphoid cells (Fujiwara et al., 2001; 
Pedraza et al., 2000; Sixt et al., 2001) . 
The laminin 5 chain was recently identified. The LAMA5 gene encoding laminin 5 was 
first discovered in mouse in 1995 (Miner et al., 1995) and two years later in human (Durkin 
et al., 1997). Laminin 5 one of the three laminin chains in laminin-511, laminin-521 and 
laminin 523, previously known as laminin-10,-11 and -15. Unlike the laminin 4, laminin 5
Figure 2: Laminin chain with 
the ,  and  arms
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appears as a cruciform molecule in rotary shadowing electron microscopy (Doi et al., 2002). 
It is currently acknowledged that laminin 5 is the most widely expressed laminin chain 
(Miner et al., 1998; Miner et al., 1995; Miner et al., 1997; Sorokin et al., 1997a; Sorokin et 
al., 1997b). Among these laminins, laminin-521 isoform has the most restricted distribution, 
for example, it can be found in the glomerular BMs of the kidney, neuromuscular junctions, 
perineurium  of  peripheral  nerves,  and  the  BM  of  arterial  smooth  muscle  cells  (Miner  and  
Patton, 1999). In spite of these data further studies need to be carried out to identify the exact 
physiological role of laminin 5 and subsequently its role in the pathogenesis of human 
diseases. 
Some examples of basement membrane-related diseases 
As examples of BM-related diseases involving type IV collagen are Alport syndrome 
and  Goodpasture  syndrome are  shortly  discussed.  Alport  syndrome is  often  associated  with  
the mutation in the gene encoding type IV collagen 5 chain (Barker et al., 1990; Tryggvason 
et al., 1993) while Goodpasture syndrome is a prototype autoimmune disease characterized 
by the formation of autoantibodies against the heterotrimeric BM collagen type IV, which 
causes a rapidly progressive glomerulonephritis. The pathogenic antibody response is in 
Goodpasture syndrome directed to the non-collagenous (Ninomiya et al., 1995) domain of the 
3 chain of type IV collagen ( 3(IV)NC1). 
Alport syndrome is a hereditary disease affecting the kidney in particular and presents 
itself with symptoms like hematuria, sensorineural hearing loss and ocular lesions with 
structural defects in the BM in the kidney, inner ear and eye. The COL4A5 mutation causes 
structural and functional defects in the type IV collagen molecule consequently in the 
glomerular BM network, vestibulocochlear nerve (statoacoustic) and eye abnormalities. It is 
primarily X chromosome-linked with mutation in the COL4A5 gene encoding the 5(IV) 
collagen chain (Barker et al., 1990; Tryggvason et al., 1993). At least 50 different mutations 
have been identified in the COLA5 gene, including single base mutations, large deletions, 
and other major rearrangements such as inversions, insertions and duplications (Tryggvason 
et al., 1993).  
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In addition to Alport syndrome and Goodpasture syndrome, diabetic nephropathy 
involves a disruption of the glomerular BM. Here due to microangiopathy the ECM protein 
deposition, for example collagen types I, IV, V, and VI; fibronectin, and laminin, are 
augmented by TGF-1, thus inducing mesangial expansion and glomerular BM thickening. 
Additionally, enzymatic degradation of ECM is low due to decreased expression of MMP-2 
and 3 and increased  expression of  tissue inhibitor of metalloproteinase (TIMP) and 
subsequently contributes to an excessive accumulation (Schena and Gesualdo, 2005; 
Tsilibary, 2003). Annother example of a BM related could be epidermolysis bullosa (EB) 
which comprise of a group of heritable blistering disorders caused by mutations in ten genes 
expressed in the cutaneous basement membrane (Tamai et al., 2009). 
PROVISIONAL MATRIX COMPONENT- VON WILLEBRAND 
FACTOR 
The usual response to injury involves an intricately orchestrated series of events that 
include coagulation, inflammation, angiogenesis, epithelialisation and fibroplasias. The first 
step, coagulation, provides hemostasis and establishes temporary ECM scaffolding for 
cellular migration.  Angiogenesis is yet another critical step in wound healing and must occur 
in  the  provisional  matrix.  The  major  ECM  components,  type  IV  collagen  and  laminins  are  
found in the subendothelial space of quiescent dermal micro vessels. During injury the 
microenvironment undergoes significant alterations to form a provisional matrix which is rich 
in von Willebrand factor, fibrinogen, thrombin, fibronectin and vitronectin (Clark et al., 
1996). This provisional matrix molecule provides essential regulatory signals for endothelial 
cell adhesion, proliferation and gene expression. Though angiogenesis is promoted by growth 
factors and various other stimuli, for example fibroblast growth factor (FGF) released at the 
sight of injury, the ECM environment regulates the cellular response (Isik et al., 1998).   
Von Willebrand factor (vWF), is a large glycoprotein encoded by a gene on 
chromosome 12. It is synthesized by vascular endothelial cells and megakaryocytes and 
circulates in the human plasma. Here it forms a noncovalent complex with coagulation with 
factor VIII, which is important for the normal survival of factor VIII. Another important 
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function of vWF is the formation of platelet plugs at sites of endothelial damage. The vWF 
binds to the exposed subendothelium and forms a bridge between the surface and the 
platelets. These function are facilitated by the peculiar structure of vWF which is arranged in 
multimers. vWF is secreted from the endothelial cells in a bipolar manner, through both the 
luminal and abluminal membranes. Through the latter some vWF is deposited into the 
vascular endothelium, where it acts as an extracellular matrix protein to bridge circulating 
platelets (Mannucci, 1998). Von Willebrand factor is not synthesized and/or stored by any 
other cells. The secretion of vWF follows three routes: 1) the constitutive secretion is a 
continuous process of release and requires no cellular stimulation; 2) the regulated release of 
vWF occurs from the Weibel-Palade bodies upon cellular stimulation, in response to 
secretagogues, or upon vascular endothelial cell damage; 3) a third pathway involves both of 
the above so that processed vWF from the Golgi complex is targeted to storage granules as in 
regulated secretion but is continuously secreted from this storage pool without provocation 
(constitutive-like secretion or basal secretion) (Johnsen and Lopez, 2008). In 
immunohistopathology vWF is therefore often used as a specific immunohistochemical 
endothelial cell marker. Its location relates to its hemostasis-specific dual function. 
MATRIX DEGRADING PROTEINASES 
Serine proteinases 
There are three serine proteinases of the chymotrypsin family in human 
polymorphonuclear neutrophilic granulocytes (PMNs), human NE, proteinase 3 and Cath G. 
They are homologous proteinases evolved from a common ancestor by gene duplication 
(Salvesen and Enghild, 1991). These serine proteases are stored in the primary or azurophilic 
granules of the PMNs.  
PMNs produce elastase in excess and the total amount of elastase in a single cell is 
estimated to be up to 3 pg (Liou and Campbell, 1995). Such a high concentration of the 
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human neutrophil enzyme is tightly regulated by compartmentalization in the primary 
granules. Upon PMN activation the azurophil granules release elastase into the extracellular 
space  but  it  remains  in  part  associated  with  the  outer  PMN  plasma  membrane  (Allen  and  
Tracy, 1995; Owen and Campbell, 1995). These serine proteinases were first identified as 
enzymes responsible for the degradation and elimination of intracellular pathogens and 
breaking down tissues at inflammatory sites (Baggiolini et al., 1979; Janoff and Scherer, 
1968) and were therefore seen as possible molecular targets for anti-inflammatory agents 
(Virca et al., 1984).  
Circulating PMNs are the first cells to reach the site of acute inflammation by 
extravasation. The PMNs extravagate to the site of inflammation to provide a primary line of 
defence against bacterial infections. The neutrophil serine proteinase damage and digest the 
phagocytosed microorganism together with NADPH-oxidase system producing reactive 
oxygen species. The neutrophil serine proteinases released from the PMNs are important in 
the regulation of the innate immunity, inflammation and infection (Bank and Ansorge, 2001; 
Wiedow and Meyer-Hoffert, 2005). They are also well known to destroy components of the 
ECM components. This paradoxical protective and destructive function has attracted great 
interest over the past decade (Bank and Ansorge, 2001). Neutrophil serine proteinases are 
implicated in a variety of infectious-inflammatory diseases, like lung disease (Kawabata et 
al., 2002; Lee and Downey, 2001; Moraes et al., 2003) and non-infectious inflammatory 
disease such as glomerulonephritis and arthritis (Liu et al., 2000; Schrijver et al., 1989).  
A proper balance between proteinases and their natural inhibitors is essential, but 
during inflammation there is a dysregulation between the protease-antiprotease balance, 
leading to activation of proinflammatory mediators. PMNs are recruited via increased IL-8 
production (Nathan, 2002; Pham, 2006; Taggart et al., 2005). In contrast to OA, patients with 
RA have  significantly  increased  level  of  Cath  G activity  (Miyata  et  al.,  2007).   It  is  still  a  
mystery to the scientific community how secreted proteinases remain enzymatically active 
and contribute to the chronicity of inflammation by cleavage of extracellular target proteins 
in an environment most often replenished with inhibitors. 
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Type IV collagenases 
As discussed earlier, the covalently crosslinked, polymeric network of type IV 
collagen provides structural integrity to BMs and synovial lining, therefore, in earlier times 
the term type IV collagenase was in frequent use for the enzyme able to degrade BM type IV 
collagen. We know them today as MMP-2 and MMP-9. These MMPs degrade several 
substrates, including gelatine, which is denatured collagen, and were also earlier known as 
gelatinase A and gelatinase B, respectively. 
The MMPs form a class of 25 enzymes that are synthesized as latent zymogens 
(Overall and Kleifeld, 2006; Page-McCaw et al., 2007). When productive conformational 
changes occur between the autoinhibitory prodomain of MMP and its catalytic domain, the 
proteolytic activity is unmasked. They are zinc-dependent endopeptidases and are capable of 
degrading essentially all ECM components. The MMPs can be synthesised by several 
different cell types such as fibroblasts, macrophages, endothelial cells, mast cells, and 
eosinophils. The activity of the MMPs can be specifically inhibited by TIMPs (tissue 
inhibitors of metalloproteinases). MMPs can be induced by various cytokines and growth 
factors. Further studies have shown that MMPs play an important role in proteolytic 
remodelling of extracellular matrix in various physiologic situations which including 
developmental tissue morphogenesis, tissue repair, and angiogenesis. Besides, MMPs also 
play a key role in excessive breakdown of connective tissue components for example in RA, 
OA, chronic ulcers, dermal photoageing, and periodontitis, as well as in tumour cell invasion 
and metastasis (Kähäri and Saarialho-Kere, 1997). With regards to BM remodelling, attention 
has long been focused on MMP-2 and MMP-9. These metalloproteinase were found to be 
widely expressed during the remodelling of normal and neoplastic tissue (Liotta and Kohn, 
2001; Masson et al., 2005; Zeisberg et al., 2006). Besides, MMPs can proteolytically activate 
and release biologically active fragments from ECM (Kähäri and Ala-Aho, 2009) 
Expression of CD147 which is an extracellular matrix metalloprotease inducer has 
been shown to be more intensely expressed in the RA synovial fibroblast than in OA 
(Konttinen et al., 2000b; Zhu et al., 2006). It can be supposed that the this increased 
expression of CD147 is in part responsible for elevated levels of MMPs. MMP-2 and MMP-9 
are strongly expressed in RA. 
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THE SYNOVIAL JOINT 
Synovium covers the non-cartilage part of the interior surface of the healthy synovial 
joint cavities and regulates in part the transport of nutrients and other molecules between the 
synovial tissue and joint cavity and the avascular articular cartilage. The synovial lining 
covering the synovial membrane consists of few cell layers of macrophage-like type A and 
fibroblast-like type B synoviocytes (Smith et al., 2003). Type A synoviocytes actively uptake 
foreign substances that are injected into the joint cavity While the type B synthesize and 
secrete ECM components including collagen, hyaluronan, proteoglycans into the interstitium 
and synovial fluid. It probably also synthesises the intercellular cementing substance 
containing BM components located between the lining cells (Iwanaga et al., 2000). 
In normal condition the synovial membrane contains blood vessels and 
lymphatic vessels (eponis et al., 1996a). Synovial membrane can be well-vascularized loose 
connective tissue, fat tissue or relatively fibrous tissue. Oxygenation and nutrition is 
facilitated from this sublining layer, in part via rich sublining microvasculature and by the 
presence of fenestrated capillaries. 
Hydrophilic hyaluronan is removed from synovial fluid and membrane via 
lymphatic vessels, with muscle pump acting as the pumping force. Fibroblasts and fibroblast-
like cells are considered to replenish mainly via local proliferation (Nykanen et al., 1986). 
Tissue macrophages are formed from monocytes migrating out of the blood stream. These 
macrophages further accumulate in the stroma of the synovial membrane and in the synovial 
lining (Dreher, 1982; Edwards and Willoughby, 1982). Mast cells are formed by recruitment 
and local differentiation of circulating precursor cells (eponis et al., 1998). It has been also 
recently demonstrated that this migration in dependent on distinct enzymes. Macrophages in 
the synovial stroma and lining play an important role in the synovial homeostasis by handling 
apoptotic cells without causing inflammation.  
Healthy synovial fluid normally contains <0.2 X 109 leukocytes per litre and <25% of 
them are polymorphonuclear neutrophilic granulocytes (PMN). Synovial fluid is considered 
as an ultrafiltrate of plasma, with hyaluronan from the fibroblast-like type B lining cells 
added.
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RHEUMATOID ARTHRITIS 
Introduction 
Rheumatoid arthritis (RA) is defined as a condition characterized by polyarticular 
swelling and morning stiffness in multiple joints, including those of the hands, with midline 
symmetry and rheumatoid nodules, 
usually presenting with rheumatoid factor 
(and/or anti-cyclic citrullinated peptide 
antibodies) and with a tendency to lead to 
bony erosion. These changes lead to joint 
tenderness and even joint pain. Usually 
inflammation is first seen in the small 
joints  of  the  hands  and  feet,  but  any  
synovial joint can be affected. RA can 
make the joints feel stiff in particular in 
the morning and makes the patient feel generally 
unwell and tired. 
Rheumatoid arthritis (RA) is the most common autoimmune musculoskeletal disease 
in human beings. It has been found in 0.5– 1.1% of the general population in studies carried 
out in Northern European and North American areas (Alamanos and Drosos, 2005). The 
cause of RA is still not known, but autoimmunity plays a pivotal role in its chronicity and 
progression of the disease. It is assumed that an unknown antigen reaches the synovial tissue 
thereby initiating a local response leading to synovitis.  
The synovial membrane comprises of two cell types, macrophage-like and fibroblast-
like  synoviocytes.  In  RA  the  synovial  membrane  is  invaded  by  T  and  B  cells  and  
macrophages (Konttinen et al., 1981). In RA the affected joints become hyperplastic due to 
the proliferation of synovial cells (Qu et al., 1994) and massive infiltration by inflammatory 
cells (Kraan et al., 1998). Consequently the synovial lining layer increases in thickness up to 
Figure 3: Synovial joint in normal 
and arthritic condition 
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10-20 cell layers and displays villus formation. As the disease progresses the fibroblast-like 
synoviocytes proliferate and macrophage-like cells are recruited from the circulation so that 
the lining becomes hyperplastic and invasive destroying the articular cartilage and the 
underlying bone (Strand et al., 2007). 
The  aetiology  and  also  the  pathogenesis  of  RA  are  still  to  a  large  extent  unknown  
(Strand et al., 2007). Earlier studies have attempted to investigate and quantify the genetic 
and environmental factors that contribute 
to  RA.  Quantitative  genetic  analysis  
conducted in the UK and Finland on 
twins using different study designs have 
shown approximately 60% heritability 
which did not differ by sex, age, age of 
onset and disease severity (MacGregor et 
al.,  2000).  On  the  other  hand  the  
environmental factors such as smoking 
strongly influences the disease risk of 
RF-seropositive RA associated with one 
of the classic genetic risk factors for 
immune-mediated diseases (the SE of HLA–DR) (Padyukov et al., 2004). In diseased 
synovium, proliferation of the synovial lining cells and infiltration of inflammatory cells 
result in hypoxic conditions in the tissue. This is because of increasing distance to the blood 
vessel (hypertrophy) and increased demand for oxygen in these vasculature-deprived 
hyperplastic regions. Therefore, reactive neovascularisation is commonly observed in these 
regions (Paleolog, 2002; Roccaro et al., 2005). It is not clearly known what initiates the initial 
proliferation of the synovial fibroblasts and the recruitment of stromal and lining 
monocytes/macrophage in the early stages of RA (Ospelt et al., 2004). It has been suggested 
that the increasing number of RA synovial fibroblast in the synovial lining layer may be due 
to an diminished apoptosis (Seemayer et al., 2003). Tumour necrosis factor- (TNF-) which 
is one of the key molecules driving inflammatory processes in RA synovium, has an 
antiapoptotic effect (Wang et al., 2006a). Apart from PMNs in RA synovial fluid, 
macrophages are key players in promoting inflammation and joint destruction in RA by 
secreting proinflammatory cytokines such as interleukin-1 (IL-1) and TNF- (Ma and Pope, 
2005). Activation of macrophages takes place in the RA synovium by several mechanisms, 
Figure 4: A 39 year old female diagnosed with 
RA. Swollen II and III PIP joints (also II and 
III MCP joints were swollen).
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for example by activation by T cells that secrete stimulatory cytokines, such as interferon-
(IFN-)  and  interleukin-2  (IL-2).  Also  direct  cell-cell  contact  between  macrophages  and  T  
cells can result in macrophage activation (Ma and Pope, 2005). RA synovial T cells are able 
to induce chemokine production by monocytes in a cell-contact-dependent manner (Beech et 
al., 2006). First and foremost, there is evidence that B cells and T cells play an important role 
in the pathogenesis of RA (Leipe et al., 2005; Samuels et al., 2005; Skapenko et al., 2005). 
Therefore in patients with RA it is not surprising to find antibodies directed against self-
antigens that can be found prior to the clinical onset of the disease (Aho et al., 1985; Leslie et 
al., 2001). 
Diagnostic criteria of rheumatoid arthritis 
The American College of Rheumatology has defined (1987) the following criteria for 
the classification of RA: 
 Morning stiffness of >1 hour most mornings for at least 6 weeks. 
 Arthritis and soft-tissue swelling of >3 of 14 joints/joint groups, present for at 
least 6 weeks 
 Arthritis of hand joints, present for at least 6 weeks 
 Symmetric arthritis, present for at least 6 weeks 
 Subcutaneous nodules in specific places 
 Rheumatoid factor at a level above the 95th percentile 
 Radiological changes suggestive of joint erosion 
At least four criteria have to be met for classification as RA.  
These criteria were primarily intended to categorize research but are also used for 
clinical diagnosis. One of the criteria is the presence of bone erosion on X-ray. Prevention of 
bone erosion is one of the main aims of treatment because it is generally irreversible. To wait 
until  all  of  the  ACR  criteria  for  RA  are  met  would  result  in  a  poor  outcome.  It  is  
recommended to treat the condition as early as possible and prevent bone erosion from 
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occurring by using combination treatment, saw tooth strategy and biologicals. The ACR 
criteria are very useful for categorising established RA, for example for epidemiological 
purposes. 
Pathomechanism regarding synovial fluid neutrophils 
The synovial fluid normally contains <0.2 X 109 leukocytes per litre, compared to 4-
10 x 109/l in peripheral blood, and <25% of them are PMNs. During inflammation a number 
of inflammatory and chemotactic mediators are released in the joints, which increase the 
vascular permeability and lead to an extensive recruitment of neutrophils and mononuclear 
cells (lymphocytes and monocytes). This migration is directed outward from the circulation 
to the site of cellular infiltrates and damaged tissue areas so that mononuclear round cells are 
in RA found in the synovial tissue and PMNs in the synovial fluid. This migration requires 
passage through the vascular endothelium and subendothelial BM and for the neutrophils, 
further through the synovial lining (Heck et al., 1990). The process of chemotaxis and 
diapedesis is not yet well understood, but it is known that the infiltration of a large number of 
neutrophils coupled with release of reactive oxygen metabolites and secretion of neutrophil 
proteinases can lead to tissue destruction (Henson and Johnston, 1987). Chemokines play a 
role in migration of circulating cells. They play a substantial role in RA by promoting 
leukocyte trafficking first into the synovium (Tarrant and Patel, 2006; Vergunst et al., 2005) 
and in the case of PMNs in particular further to the synovial fluid. Earlier, several studies 
have suggested that BM degradation mediated by neutrophils occur mainly as a result of 
secretion of the serine proteinases- elastase and Cath G (Davies et al., 1978; Mainardi et al., 
1980; Pipoly and Crouch, 1987; Vissers et al., 1984). Enzyme mediated degradation of BM 
can be augmented by the reactive oxygen metabolites produced by the neutrophil, and/or by 
the endothelial cells or injured tissue (Shah, 1989). There is evidence that type IV collagen is 
a potential target for NE (Davies et al., 1978; Mainardi et al., 1980; Pipoly and Crouch, 1987; 
Vissers et al., 1984).  
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Pharmacology: Biological therapies of rheumatoid arthritis 
Four biological therapies which inhibit TNF- are currently in the market, these 
therapies include three monoclonal antibodies infliximab, adalimumab and certolizumab 
pegol and a fusion protein of the extracellular domain of p75TNF- receptor, etanercept. 
However,  monoclonal  antibodies  that  target  T-cell-surface  antigens  were  the  first  to  be  
systematically  tested  in  RA.  These  agents  were  capable  of  reversing  autoimmunity  and  
transplant rejection (Cobbold et al., 1992). Co-stimulatory signal inhibitor, cytotoxic T 
lymphocyte-associated protein 4-immunoglobulin abatacept, was recently approved for the 
treatment of RA. Apart from targeting the T-cells promising clinical findings have emerged 
using monoclonal antibodies and fusion proteins targeting B cell surface antigens and the 
TNF family of B-cell-survival factors. These include rituximab (anti-CD20), epratuzumab 
(anti-CD22) and belimumab (anti-B-lymphocyte stimulator/B-cell-activating factor of the 
TNF family, anti-BLyS/BAFF). 
The use of rituximab in RA was based on the observation in lymphoma patients with 
co-existing arthritis. Even though the B-cell depletion from the peripheral blood can be rapid, 
the maximum therapeutic effect in RA occurs at or after 12 weeks (Leandro et al., 2006). 
Anakinra which is an IL-1 receptor antagonist haven’t proven to be successful while 
tocilizumab which is an IL-6 receptor antagonist was approved by the European Medicines 
Agency (EMEA) in 2009 for the treatment of RA. 
Monoclonal antibodies against integrins have gained considerable interest in the 
recent years. The discovery of a number of small-molecule integrin antagonists which could 
be either a peptide or a nonpeptide peptidomimetics that would have the ability to inhibit 
various integrins and therefore be useful in treating chronic diseases such as RA (et al., 
2009)
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THE SALIVARY GLAND 
Saliva is the major product of the salivary glands and its production ranges to about 
one and a half litre per day. The composition of the saliva is unique and it functions in the 
preliminary digestion of food, maintains moisture 
in the oral cavity thereby maintaining the health of 
the teeth and mucosa. The components of saliva 
include various digestive proteins, glycoproteins 
(mucus), ions, water and immunoglobulin A 
(IgA). The major salivary glands in humans are 
the submandibular gland which produces 70% of 
the saliva, the parotid gland producing about 25% 
of amylase rich saliva. The submandibular, parotid 
and the sublingual glands that can be collectively 
called as tubuloacinar glands owing to the flow of 
saliva from the secretory structure known as the 
acini into the oral cavity via a branching tubular 
system. The submandibular glands are mixed 
seomucous glands whereas sublingual gland contain mucous producing acini parotid gland 
only contains serous acini. 
The saliva from the acinus flows into the intercalated ducts. The intercalated ducts 
then lead saliva into the secretory ducts. These striated ducts contain very high density of 
mitochondria. In light microscope these mitochondria are arranged in a vertical orientation to 
the longitudinal axis of the duct inside similarly oriented apical plasma membrane folds. 
Finally saliva flows to oral cavity via intralobar, interlobular and secretory ducts. The cells of 
the striated duct modify the saliva by the addition of ions and water by active transport. These 
water and ions are derived from the surrounding blood capillaries  
The saliva contains electrolytes and many salivary proteins, including 
immunoglobulins and antimicrobial proteins, apart from water. Maintenance of this moist 
environment is of prime importance not only for healthy teeth but also for other 
microbiological and medical reasons.  
Figure 5: Salivary gland showing the 
duct system 
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SJÖGREN’S SYNDROME 
Introduction 
The credit for the first description of SS is generally given to Mikulicz, who in 1892 
described a 42 year old man with bilateral enlargement of the parotid and lacrimal glands 
associated with small round cell infiltrates. But the term Mikulicz’s syndrome could 
encompass many different entities, including tuberculosis, other infections, sarcoidosis and 
lymphoma and is not much used today. The Swedish ophthalmologist Henrik Sjögren in 1933 
described in his thesis clinical and histological findings in 19 women, 13 of whom had 
probable RA, with dry mouth and eyes (Sjögren, 1933). SS is usually divided into primary SS 
(pSS), if it evolves without co-existing connective tissue disease and secondary if it is 
associated with another connective tissue disease, usually RA, systemic lupus erythematosus 
or scleroderma (Moutsopoulos H. M, 1994). 
After the migration of dendritic cells and lymphocytes to the gland in response to the 
chemokines and adherence to specific vascular adhesion molecules, lymphocytes interact 
with the dendritic cells and epithelial cells (Jonsson et al., 2003). The activation of the T and 
B lymphocytes in the glands (also other lymphoid tissue), occur by means of HLA-DR-
restricted antigen presenting cells in the presence of co-stimulatory molecules. This acquired 
immune system perpetuates immune response leading to the production of memory 
lymphocytes and auto antibodies (Sawalha et al., 2003). Extraglandular manifestations occur 
as a result of lymphocytic infiltration into other tissue or generation of pathogenetic 
autoantibodies and immune complexes. It should also be considered that innate and adaptive 
immune systems are mutually costimulatory (Santiago-Raber et al., 2003).  
Robert Fox proposed a pathogenesis model for SS in the journal the Lancet in 2005 
(Fox, 2005), as follows: 
a) An initial insult (viral or non-viral) to the gland leading to cellular necrosis or apoptosis 
with subsequent expression of the Sjögren’s SS-A protein on the glandular-cell surface 
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b) Production of cytokines by the injured gland that up-regulate chemokines and cell 
adhesion molecules on the high endothelial venules of the gland, a process that promotes the 
migration (homing) of lymphocytes and dendritic cells into the gland 
c) Production of antibodies to SS-A antigen presented by HLA-DR-positive antigen 
presenting cells by B lymphocytes under the influence of T-helper lymphocytes 
d) Formation of immune complexes containing anti-SS-A antibodies and ribonucleoprotien 
that binds to dendritic cells in the gland by via Fc type IIa receptors and after internalization 
stimulates their Toll like receptor 7. 
e) Production type 1  and  interferons by the plasmacytoid dendritic cells, which further 
perpetuate the process of the lymphocyte homing, lymphocyte and MMP, and apoptosis of 
glandular cells. 
The primary SS is a systemic autoimmune disorder with a population prevalence of 
about 0.5-1% and with a male to female ratio of 1:9. The prevalence of secondary SS appears 
to vary between different connective tissue diseases with prevalence of 9-19% having 
reported in SLE patients, 4-31 % in RA patients, and 14-20 % in scleroderma patients 
(Avouac et al., 2006; Gilboe et al., 2001; Manoussakis et al., 2004; Ramos-Casals et al., 
2007). SS is one of the three most common autoimmune disorders (Binard et al., 2007; 
Pillemer et al., 2001). There are two age peaks of primary SS, the first being after menarche 
during the 20s to 30s and the second after menopause in the mid 50’s (Fox, 2005).  
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Diagnostic criteria of Sjögren’s syndrome 
Various sets of criteria have been used for the classification of SS. The Copenhagen 
criteria from 1984 (Manthorpe et al., 1986), the preliminary European Community criteria 
from 1993 (EC93) (Vitali et al., 1993), the modified European Community criteria from 1996 
(EC96) (Vitali et al., 1996) and the American-European Consensus criteria from 2002 (Vitali 
et al., 2002). According to the later, four inclusion criteria must be fulfilled to be classified as 
classical primary SS and must always include one of the two autoimmune criteria. The 
inclusion criteria’s are: 
 dry eyes for more than 3 months, gritty feeling in the eyes or use of artificial 
tears for more than 3 times a day, 
 dry mouth for more than 3 months, enlarged parotid glands or a need to drink 
water when eating dry food.  
 less than 5 mm/5 min of resting lacrimal fluid in Schirmer-1 blotting paper test 
or a damage score of the conjunctiva and cornea of at least 4 in Rose Bengal 
or other vital stain (Lissamine Green or fluorescein) test 
 pathological scintigraphy, sialography or sialometry 
 Focus score (the number of lymphocyte infiltrates/4 mm2) is at least one in the 
labial salivary glands 
 SS-A/Ro and/or SS-B/La autoantibodies 
For the evaluation of the presence and degree of autoimmune inflammation in 
exocrine glands, minor salivary glands can be easily obtained by a lower lip biopsy or 
actually LSG biopsy for histopathological evaluation. The presence of focal sialoadenitis, 
represented by a focus of lymphocytes (i.e. 50) aggregated around salivary gland ducts, is 
characteristic of the autoimmune inflammation in the exocrine glands (Chisholm and Mason, 
1968; Greenspan et al., 1974). The number of foci found in a cross section of 4 mm2 of 
glandular tissue 1 is characteristic of SS (Vitali et al., 2002).  
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Pathomechanisms of Sjögren’s syndrome 
After indepth study, which still continues, of the underlying cause of SS it could 
broadly be considered multifactorial. For research purpose the affected tissue can be obtained 
easily in SS by minor salivary gland biopsy. The initial steps in pathogenesis have been 
suggested to involve glandular vascular endothelial cells, the glandular epithelial cells, or the 
underlying stromal and dendritic cells (Tapinos et al., 1999). 
The apoptosis may play a vital role in the pathophysiology of salivary gland, such as 
the destruction of the salivary acini in SS (Manganelli and Fietta, 2003). Defects in the 
apoptosis in lymphocytes could result in the accumulation of lymphoid cells in the affected 
tissue. An increase in the apoptosis of the exocrine gland epithelial cells could impair 
secretory function and the resulting exposure of intracellular autoantigens, might evoke or 
enhance autoantibody production (Itoh et al., 1991). The apoptotic processes in salivary 
glands  of  patients  with  SS are  not  clear.  A potential  source  for  renewal  of  lost  acinar  cells  
could be progenitor cells in the intercalated ducts (Eversole, 1971; Kishi et al., 2006; 
Vugman and Hand, 1995). These progenitor cells contribute to the renewal of acinar cells via 
differentiation, though acinar cells may also be renewed by autologous cell division (Denny 
and Denny, 1999). Salivary gland intercalated duct was the source of the HSG cell line 
(Shirasuna et al., 1981), which forms a potential model for the repopulation of damaged 
acinar cells from their progenitors. These HSG cells are capable of morphodifferentiation to 
acinar cells on culture on BM extracts (Matrigel) upon contact with laminin 1 chain, a 
component of the BM Lm-111. These early morphological and functional differentiation 
events have been previously studied by several investigators (Crema et al., 2006; Hoffman et 
al., 1996; Jung et al., 2000; Royce et al., 1993; Vag et al., 2007; Zheng et al., 1998), but only 
recently this same laminin Lm-111 was described in the BM of the LSG acini (Laine et al., 
2004). Recently these cells and their LSG counterparts have been shown to contain intracrine 
dehydroepiandrosterone prohormone metabolizing enzymes (Spaan et al., 2009) and to be 
responsive to it and its metabolite (Laine et al., 2007). 
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Pharmacological treatment of Sjögren’s syndrome 
The treatment of SS is symptomatic including management of non-visceral 
manifestations and visceral involvement. Arthralgia and myalgia are examples of non-
visceral manifestations and are treated with salicylates, other non-steroidal anti-inflammatory 
drugs, coxibids and hydroxychloroquine. Glucocorticosteroids are used in patients with SLE 
with secondary SS but can cause adverse events. Decrease in salivary flow may result in 
dysphagia and decrease in oesophageal motility thereby lowering the tolerance to NSAIDs in 
patients  suffering  from  arthralgia  (Belafsky  and  Postma,  2003).  In  SS  with  the  visceral  
involvement like vasculitic skin lesion, pneumonitis, nephropathy and nephritis 
hydroxylchloroquine, glucocorticosteroids, azathioprine and methotrexate can be used (Fox, 
2005).
One  of  the  most  commonly  used  forms  of  systemic  treatment  in  SS  is  the  use  of  
secreatagogues pilocarpine and cevimeline or agents changing the consistency of saliva such 
as bromhexine (Misawa et al., 1985; Vlachoyiannopoulos, 1998). These drugs exert their 
effects by stimulating mainly the M3 muscarinic receptor for acetylcholine, and they have 
been shown to increase the salivary flow rates and ameliorate oral and ocular symptoms in 
placebo-controlled trials (Petrone et al., 2002; Thanou-Stavraki and James, 2008; Vivino et 
al., 1999). The M3 isoform of the muscarinic receptor is an important neurotransmitter 
receptor involved in salivary fluid secretion (Bacman et al., 1998; Bacman et al., 1996; Fox et 
al., 2001). In primary SS and secondary SS the presence of antimuscarinic M3 receptor 
antiantibody  has  been  reported  (Waterman  et  al.,  2000).  However,  the  presence  of  the  M3  
receptor elsewhere in the body makes some patients experience adverse effects of the drug, 
e.g. sweating, abdominal distress, and aggravated irritable bladder symptoms (Thanou-
Stavraki and James, 2008). 
Rituximab has shown to be useful in primary SS associated non-Hodkin’s lymphoma 
and it also seems to be able to improve systemic manifestations of SS, such as fatigue, 
synovitis, arthralgia, cryoglobulinaemia-related vasculitis, neurological, renal and pulmonary 
involvement (Isaksen et al., 2008). 
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AIMS OF THE STUDY
The BM is essential for providing support and anchorage for cell they also play a role 
in the intercellular communication. It also sequesters various growth factors acting as a local 
depot. Amongst the other components of the ECM, type IV collagen and laminins form the 
major part of its composition. Therefore we aimed to identify the composition of these major 
components in the BM in two specific tissues, namely the labial salivary gland and the 
synovial  membrane.  These  two  tissues  are  in  particular  greatly  affected  in  SS  and  RA,  
respectively, which fall into the class of rheumatic diseases. 
Subsequently we went a step further to investigate the presence of the vascular 
endothelial cell marker which is a provisional matrix component- von Willebrand factor, in 
the healthy and diseased labial salivary gland.  
Specifically, the aims of the thesis were; 
1) to define the  chain composition of the intercellular cementing substance between 
the macrophage-like type A and the fibroblast-like type IV collagen in the synovial 
lining or intima in RA compared to similar/analogous lining/lining-like structures in 
OA, aseptic loosening of a joint prosthesis and traumatized joints. 
2) to define the  chain composition of the tubuloacinar BM in labial salivary glands in 
SS compared to labial salivary glands from healthy controls 
3) based  on  earlier  studies  in  other  anatomical  areas,  to  define  the  eventual  role  of  
laminin 4 and laminin 5 chains in the intercellular cementing substance in synovial 
lining in relationship to neutrophil migrating from the intravascular compartment 
through synovial membrane and lining to synovial fluid, again comparing RA with 
OA, aseptic loosening and trauma. 
4) to define the state of the vascular endothelium in tubuloacinar labial salivary glands in 
SS compared to healthy control glands by using von Willebrand factor as a vascular 
endothelial cell marker and by following the eventual activation and/or damage of 
these cells by analyzing eventual release and deposition of von Willebrand factor in 
the BM and perivascular interstitial matrix.  
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MATERIALS AND METHODS
Ethical issues and approval 
The use of human tissue samples for all the studies in this thesis was approved by the 
Ethical Committee of the Joint Authority for the Hospital District of Helsinki and Uusimaa, 
HUS, Finland. 
Synovial tissue and labial salivary gland samples 
The synovial samples investigated for type IV collagen  chains included frozen 
sections from ten trauma, five OA, five prosthesis loosening (synovial membrane-like 
interface tissue around aseptically loosening prosthesis with an ongoing foreign body 
synovitis) and ten rheumatoid arthritic synovial tissue samples for immunohistochemical 
staining unless otherwise mentioned. Labial salivary gland tissue samples were obtained 
either from patients with SS (n = 10) or from healthy controls (n = 10). The diagnosis of SS 
was based on the American-European consensus criteria for SS (Miner and Sanes, 1994; 
Vitali et al., 2002). For analysis of laminin 4 and laminin 5 in the synovial tissue frozen 
tissue sections were taken from five traumas, five prosthesis loosening, five OA and five RA 
patients. Paraffin embedded sections of synovial tissue were used to study NE and Cath G in 
synovial tissue.
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Antigen Specificity Type Source and reactivity Antibody code 
Type IV collagen 1/2 Monoclonal Mouse anti human M3F7 
Type IV collagen 3 Polyclonal Rabbit anti human -
Type IV collagen 4 Polyclonal Rabbit anti human -
Type IV collagen 5 Polyclonal Rabbit anti human -
Type IV collagen 6 Polyclonal Rabbit anti human -
Laminin 4 Monoclonal Mouse anti human 168FC10 
Laminin 5 Monoclonal Mouse anti human 4C7
CD 68 Monoclonal Mouse anti human EBM11
MMP-2 Polyclonal Goat anti human AF902 
MMP-9 Monoclonal Mouse anti human MAB3309 
Lactoferrin Polyclonal Rabbit anti human A 0186 
Cath G Monoclonal Mouse anti human 19C3
NE Monoclonal Mouse anti human M 0752 
Von Willebrand factor Monoclonal Mouse anti human M 0616 
Immunoperoxidase staining of tissue sections 
For immunohistochemistry tissue samples were snap frozen in dry ice precooled 
isopentane in OCT embedding medium (Sakura Finetek Europe B.V, Zoeterwoud, 
Netherlands) and stored at -70ºC. Samples were cut to 5 m tissue sections, air dried at 
+22°C for one hour. Acetone was used for fixation of frozen sections for 5 minutes at +4°C. 
Type IV collagen 3, 4, 5 and 6 chains immunoreactivity was revealed by denaturing the 
respective frozen sections in acidic urea-glycine (0.1 M glycine, 6 M urea, pH 3.5) for 60 
minutes at +4°C as described elsewhere (Miner and Sanes, 1994). Paraffin embedded 
sections were used to stain NE and Cath G. The paraffin sections were deparaffinised in 
xylene, rehydrated through a graded ethanol series and washed in PBS. For antigen retrieval 
Table 2: List of antibodies used  
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the tissue sections from RA and OA patients were pretreated with 0.4% pepsin in 1N HCl for 
retrieval  of  NE,  while  for  the  detection  of  Cath  G  the  antigens  were  retrieved  by  heat  
treatment for 30 minutes in 0.01 M sodium citrate buffer, pH 6.0, using MicroMED T/T 
Mega Laboratory Microwave Systems (Milestone, Sorisole, Italy).  For  blocking  of  the  
endogenous peroxidase activity 0.3 % H2O2 in methanol was used for 30 minutes. After 
washing with 10 mM phosphate buffered 140 mM saline, (PBS, pH 7.4), the sections were 
incubated in the following reagents at +22°C unless otherwise mentioned 1) normal horse 
serum (for monoclonal mouse anti-human antibodies), normal goat serum (for polyclonal 
rabbit anti-human antibodies) or normal rabbit serum (for polyclonal goat anti-human 
antibody) for 3 hours at +22°C to block nonspecific binding sites of the respective secondary 
biotinylated anti-Ig antibodies; 2) monoclonal mouse-antihuman IgG	 antiserum to type IV 
collagen 1/2 chain  (1:1000 in 0.1 % BSA-PBS, M3F7, Developmental Studies Hybridoma 
Bank, University of Iowa, IA), monoclonal mouse anti-human NE IgG1 (1:50, M 0752, Dako, 
Glostrup, Denmark), monoclonal mouse anti-human Cath G IgG1 (1:50, NCL-CATH-G, 
Novocastra Laboratories, Newcastle, UK), monoclonal mouse anti-human vWF (1:100 in 0.1 
% BSA-PBS, M0616, DAKO, Glostrup, Denmark), polyclonal goat anti-human MMP-2 IgG 
(1:200 in 0.1 % BSA-PBS, (R&D systems, Minneapolis, MN), polyclonal rabbit anti-human 
type IV collagen 3(IV), 4(IV), 5(IV)  and  6(IV) chain IgG (1:500 in 0.1 % BSA-PBS) 
overnight at +4°C. The 3(IV), 4(IV)  and  5(IV) antibodies were a gift from Professor 
Jeffrey Miner (Dept Internal Medicine, Washington University School of Medicine, St. 
Louis,  MO)  and  the  6(IV)  antibody  from  Professor  Raghu  Kalluri  (Division  of  Matrix  
Biology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, 3) 
biotinylated  horse anti-mouse IgG, Biotinylated goat anti-rabbit IgG or Biotinylated rabbit 
anti-goat IgGsecondary IgG (Vectastain ABC Kits, 1:200 in 0.1 %  BSA-PBS, Vector 
Laboratories, Burlingame, CA), 4) avidin-biotin-peroxidase complex (ABC, 1:200 in H2O,
Vector Laboratories), 5) a combination of 0.023 % 3,3 diaminobenzidine  tetrahydrochloride 
and 0.006 %  H2O2 for 7 minutes. Finally, 6) the slides were counterstained in haematoxyline, 
dehydrated and mounted in Mountex (Mountex, HistoLab, Gothenburg, Sweden). An 
irrelevant mouse IgG was used showing specificity to glucose oxidase of A. niger not present 
or inducible in human tissues instead of the primary specific mouse anti-human IgG1 and 
rabbit IgG diluted 1:1000 in BSA-PBS were used as the negative staining controls. 
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Immunofluorescence staining for laminin 4 and laminin 5
The samples were fixed in acetone at -20°C for 10 minutes, and thoroughly rinsed in 
0.1  %  Triton-X  in  PBS,  and  washed.  The  sections  were  incubated  serially  at  +22°C  in  
humidified chambers in 1) normal goat serum (1:50, Dako, Glostrup, Denmark) for one hour, 
2) monoclonal mouse anti-human laminin 4 IgG1 (1:50, 168FC10; 11), monoclonal mouse 
anti-human laminin 5 IgG2a (1:10, 4C7; 12,13), 3) conjugated goat anti-mouse IgG (1:200, 
Alexa Fluor 568; Molecular Probes, Eugene, OR) for the laminin 4 antibodies and goat anti-
mouse IgG (1:200, Alexa Fluor 488; Molecular Probes, Eugene, OR) for the laminin 5
antibodies, all at +22°C for 60 minutes. Between the steps, the sections were washed 3x5 
minutes  in  PBS,  and  after  the  last  step  also  once  in  distilled  water  before  mounting  in  
Vectashield® (Vector Laboratories, Burlingame, CA).  
Double immunofluorescence staining  
Type IV collagen with MMP-9 and CD68 
Sections from five traumas and five RA patients were first fixed in acetone at -20°C 
for 10 minutes, then thoroughly rinsed with 0.1 % Triton-X in PBS and washed in PBS. The 
sections were incubated serially at +22°C in a humidified chamber with the following 
reagents respectively 1) normal goat serum (diluted 1:50, Dako, Glostrup, Denmark) for 2 
hours, 2) polyclonal rabbit anti-human type IV collagen IgG (Eurodiagnostics, Apeldoorn, 
The Netherlands) together with monoclonal mouse anti-human MMP-9 IgG	 (Chemicon 
International Inc., Temecula, CA) or monoclonal mouse anti-human CD68 (a macrophage 
marker) IgG	 (Dako, Glostrup, Denmark), i.e. a mixture of two antibodies (CD68 and MMP-
9 or CD68 and type collagen IV) for 90 minutes at +22°C, 3) a mixture of Alexa Fluor 568 
conjugated goat anti-rabbit IgG (diluted 1:200, Molecular Probes, Eugene, OR) and Alexa 
Fluor 488 conjugated goat anti-mouse IgG (diluted 1:200, Molecular Probes, Eugene, OR) 
for 60 minutes at +22°C, 4) To-Pro 3 (diluted 1:1000, Molecular Probes, Eugene, OR) for 
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nuclear staining for 15 minutes at +22°C. Between the steps, the sections were washed in 
PBS, and after the last step also once in distilled water before mounting in Vectashield®
(Vector Laboratories, Burlingame, CA). All antibodies were diluted in 0.1 % BSA-PBS.  
Laminin 5 and lactoferrin 
After fixation in acetone at -20°C for 10 minutes, sections from RA patients were  
thoroughly rinsed with 0.1% Triton X-100 in PBS and washed in PBS. The sections were 
incubated serially at +22°C in a humidified chamber as follows: 1) normal goat serum (1:50; 
Dako, Glostrup, Denmark); 2) 37g/ml polyclonal  rabbit anti-human lactoferrin 
immunoglobulin (Dako, Glostrup, Denmark) together with monoclonal mouse anti-human 
laminin 5 IgG2a (1:10 in 0.1 % BSA in PBS) (4C7; 12); 3) a mixture of Alexa Fluor 568–
conjugated goat anti-rabbit IgG and Alexa Fluor 448–conjugated goat anti-mouse IgG (1:200; 
Molecular Probes, Eugene, OR), all for 60 minutes at +22°C; between the steps the sections 
were washed 3x5 minutes in PBS, and after the last step also  once in distilled water before 
mounting in Vectashield (Vector Laboratories, Burlingam, CA).  
Microscopic assessment and image analysis 
The avidin-biotin-peroxidase stained slides for type IV collagen  chains, Cath G, NE 
and vWF were analyzed under a light microscope (Leitz, Wetzlar, Germany), coupled with a 
12 bit cooled CCD camera (Sensicam, PCO imaging, Kelheim, Germany). 
The vWF stained slides were microscopically evaluated for of the number of vWF 
positive capillary blood vessels. This was done with an Olympus BH-2 light microscope 
(Olympus Corp., Tokyo, Japan) coupled for morphometric assessment with a CCD camera 
(Panasonic WV-CD130L, Matsushita Electric Industrial, Osaka, Japan) and linked to a 
semiautomatic image analysis Video Interactive Display System (VIDAS 2.1) and processing 
(Videoplan 2.2, Kontron Elektronik, Münich, Germany) systems. The immunohistopathology 
of the specimens were analyzed under ×250 magnification by consecutive fields from at least 
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three tissue sections as described in a paper from our group by A. eponis (eponis et al., 
1996a). In addition, the area of the vWF delineated (outer margin of the endothelium) 
capillary blood vessels were calculated in labial salivary gland parenchyma (acinar areas) and 
is expressed as m2 per mm2 labial salivary gland reference tissue. Post-capillary veins and 
arterioles were excluded from these calculations. In addition, the numbers of capillary blood 
vessel profiles per mm2 were calculated. For both calculations, connective tissue septa, 
interlobular, intralobular and striated ducts and the periductal areas surrounding them were 
excluded so that only parenchymal acinar containing tissue was calculated. 
The immunofluorescent and double immunofluorescent labelled sections were 
observed under the fluorescence imaging microscope Olympus AX70 (Olympus, Vienna, 
Austria) coupled with a CCD camera. Immunoperoxidase stained slides were analyzed under 
x400 magnification using a light microscope (Leitz, Wetzlar, Germany), coupled with a 12 
bit cooled CCD camera (Sensicam, PCO imaging, Kelheim, Germany). 
Confocal microscopy and image collection were carried out using a Leica TCS SP2 
system (Leica Microsystems GmbH, Mannheim, Germany) with HCX PL APO CS 63/1.40 
objective, and 488, 568 and 633 nm laser excitation lines for Alexa Fluor 568 and 488 
conjugate and the DNA specific TO-PRO-3 probe, respectively. Image stacks were acquired 
using sequential scanning, standardized 160 nm z-sampling densities and volume depth of 3.0 
μm to visualize the basal membrane constituent collagen IV and CD68 and MMP-9 
immunoreactivities. 
Cell cultures  
Synovial fibroblast cell lines were established in the following manner. Synovial 
membrane samples were collected from three women suffering from OA, who underwent 
total hip replacement (one patient, age 79 years) or knee arthroscopy (two patients, ages 60 
and 92 years). Synovial fibroblasts were established using explant culture method. Briefly, 
tissue samples were minced to pieces and left overnight in RPMI-1640 medium 
(BioWhittaker, Liege, Belgium) containing 10 % fetal bovine serum (BioWhittaker, Liege, 
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Belgium)  and  10  %  penicillin/streptomycin.  Next  day,  the  media  was  changed  and  the  
concentration of antibiotics was decreased to 1 %. The media was changed twice a week and 
after about 60 % of the dish area was covered with monolayer of cells, the tissue pieces were 
removed and the cultures were allowed to grow to confluence. When such cells from the 3rd –
5th passage were stained using proline-4-hydroxylase as a fibroblast marker and CD163 as a 
macrophage marker, the proportion of the proline-4-hydroxylase positive spindle shaped (= 
fibroblast-like) cells > 99 %, whereas the proportion of the CD163 positive macrophages < 
1% (data not shown). These cells show other characteristics of fibroblasts as they are Hsp47, 
vimentin and fibronectin positive. Z1 Coulter Particle Counter (Beckman Coulter) was used 
for cell counting. 
Human submandibular gland (HSG) cell line was originally established by Professor 
Mitsunobu Sato (Tokushima University, Japan) (Shirasuna et al., 1981) and was obtained as a 
gift from Dr. Marc Kok from the Netherlands. HSG cell line is a human submandibular gland 
cell line with a intercalated duct cell phenotype, which can be differentiated to acinar 
phenotype by culture on BM-like Matrigel (BD Biosciences, San Jose, CA) which contains 
laminin-111. HSG cells were cultured with or without growth factor-depleted Matrigel in 
DMEM/F-12 Nut Mix medium (Gibco BRL, Grand Island, NY) supplemented with 10 % 
fetal calf serum, 2 mM glutamine, 100 U/mL penicillin and 100 g/mL streptomycin. Cells 
were stimulated with or without 100 μM DHEA (Fluka, St. Louis, MO) (diluted in absolute 
ethanol) for 72 hours. These stimulations were performed in serum free media. 
LSG samples were minced into pieces (approximately 2 mm3), put into a 6-well plate 
and left overnight in DMEM/F-12 medium (Gibco BRL, Grand Island, NY) containing 10 % 
fetal calf serum with 2 mM L-glutamine, 1000 U/ml penicillin, 1 mg/ml streptomycin (10 x) 
and 2.5 μg/ml amphotericin B (Fungizone, Gibco BRL, Grand Island, NY) solution. The next 
day,  the  medium  was  changed  to  basal  DMEM/F-12  medium  with  10  %  charcoal  stripped  
fetal calf serum, 2 mM L-glutamine, 100 U/ml penicillin, 0.1 mg/ml streptomycin (1x 
solution) and 2.5 μg/ml Fungizone. These LSG explants were then cultured without and with 
100 M DHEA for 72 hours. 
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RNA isolation and cDNA synthesis 
The protocol for the stimulation of the fibroblasts was as follows. In a 6-well plate 105
cells/well  were  grown  to  confluence.  Cells  from  two  parallel  wells  were  used  for  RNA  
extraction. The cells were stimulated for 48 hours with 0.1, 1 and 10 ng/ml recombinant 
human TNF- or recombinant human IL-1, both from R&D, Minneapolis, MN. Total RNA 
from  cells  was  isolated  using  TRIzol  reagent  (Invitrogen,  Paisley,  UK).  RNA  quality  was  
confirmed  with  ethidium  bromide  stained  1  %  agarose  gel.  The  mRNA  was  isolated  with  
magnetic (dT)25-polystyrene beads (Dynal, Oslo, Norway). mRNA concentration was 
measured spectrophotometrically and cDNA was synthesized from 50 ng of sample mRNA 
using (dT)12-18 primers and Superscript enzyme, followed by RNase H treatment (SuperScript 
Preamplification System, Invitrogen, Paisley, UK).  
From the HSG cells the total RNA was isolated using the Trizol protocol (Invitrogen, 
Carlsbad, CA) followed by mRNA extraction with the Dynabeads mRNA Purification Kit 
(Dynal,  Oslo,  Norway).  Tissue  RNA was  isolated  with  High  Pure  RNA Tissue  kit  (Roche,  
Basel,  Switzerland).  Complementary  DNA  synthesis  was  performed  with  SuperScript  First  
Strand cDNA Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA) according to the 
manufacturer’s instructions. 
Quantitative real time polymerase chain reaction  
Quantitative PCR was run using 4.8 ng first strand cDNA and 0.5 mM primers in 
LightCycler® PCR mix in LightCycler® PCR machine (Roche, Mannheim, Germany). qPCR 
runs were repeated twice with each sample. For primers, the sequences were searched using 
the NCBI Entrez Search system and sequence similarity searches were done using NCBI 
Blastn program. The primers were designed, if possible, to produce an amplicon that 
extended over two different exons. For quantitative PCR standard curve, the gene of interest 
was amplified in PCR reaction, extracted from agarose gel and cloned into pCRII-TOPO 
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vector (Invitrogen, Paisley, UK). After identification of the plasmid by restriction enzyme 
analysis and sequencing, the concentration was determined spectrophotometrically and serial 
dilutions were prepared for quantitative PCR analysis. The copy numbers of mRNAs were 
determined with two separate runs for all samples and normalized against 1x106
housekeeping -actin gene. 
Statistical analyses 
Statistical tools available in Microsoft Excel 2003 (Microsoft Corporation, Seattle, WA, 
USA) were used to perform the statistical analysis on the data obtained from qRT-PCR 
experiments. Results are presented as mean ± standard deviation. Student’s t test was used for 
pair-wise comparisons. The mean ± standard error of the mean values and/or percentage 
changes from the baseline in case of vWF positive blood vessels were calculated and the 
values were compared with Wilcoxon signed rank test, using SPSS for Windows V.16.0 
software (SPSS Inc., Chicago, IL, USA). Student’s t test was used for pair-wise comparisons 
and the level of significance was set at 0.05.  
Synovial fluid samples 
The synovial fluid samples that were used were obtained from eight patients that had 
either mildly inflamed traumatic synovial fluid (synovial fluid leukocyte counts < 5 x 109
cells/l, n = 4) or relatively severely inflamed rheumatoid synovial fluid samples (synovial 
fluid leukocyte counts 5-50 x 109 cells/l, n = 4). 
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Gelatine zymography 
Synovial fluid samples were analyzed for the gelatinase activity using gelatine 
containing sodium dodecyl sulphate-polyacryl amide electrophoresis (SDS-PAGE) under 
non-reducing condition. Gelatinase zymography activity standards were used (Chemicon 
International Inc., Temecula, CA). 15 μl aliquots of 1:50 PBS diluted synovial fluid samples 
were  run  on  a  7.5  % gelatine  acrylamide  gel  (Bio-Rad Laboratories  Inc.,  Hercules,  CA)  at  
200V for one hour, after which the gel was carefully removed from the plates and washed in 
0.05M Tris-HCl, 0.02 % (w/v) NaN3, pH 7.5 and 2.5 % Tween 80 for 30 minutes with 3 
washings in between. The gel was washed in 0.05 M Tris-HCl, 0.02 % NaN3, pH 7.5, 2.5 % 
Tween 80, 1μM ZnCl2 and  5mM  CaCl2 for 30 minutes at +22°C. Finally, the gel was 
incubated in the incubation buffer 1μM ZnCl2 and 5mM CaCl2 overnight at +37°C and then 
stained with 1.2 mM Coomassie Brilliant Blue (Serva, Heidelberg, Germany) for one hour. 
Destaining was done with destaining solution containing 70 % water, 20 % methanol and 10 
% glacial acetic acid. The bands were visible as light bands against a dark blue background.  
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RESULTS
Type IV collagen  chains in synovial lining 
Immunohistochemical staining for type IV collagen  chains 
The synovial lining showed strong signals with immunohistochemical labelling for 
collagen 1/2(IV) chains in traumatic synovial membrane samples and also 5(IV) and 6(IV)
chains were seen in the synovial lining although their labelling were relatively weak 
compared to 1/2(IV) chains and vascular BM 5(IV)  and  6(IV)  chains.  On the  other  hand  
collagen 3(IV) or 4(IV) chain did not show any labelling in immunohistochemical staining. 
The results were similar to those seen in trauma patients and also in synovial membrane in 
OA and in synovial membrane-like interface tissue around aseptically loosened total hip 
replacement implants. In contrast to the OA, trauma and synovial membrane-like interface 
tissue control samples, in RA synovial lining not only 5(IV) and 6(IV),  but  also  1/2(IV)
were very weakly expressed (Figure 6). To exclude false positive staining, an irrelevant 
immunoglobulins of the same class and subtype, using the same concentrations as were used 
for immunolabeling (data not shown). 
Quantitative RT-PCR of collagen type IV -chains in synovial fibroblasts 
To confirm the immunohistochemical observations quantitative RT-PCR was done to 
estimate the collagen (IV) chains at messenger RNA level. Three synovial fibroblast cell 
lines were grown and each of them were stimulated and analyzed separately. In spite of 
significant differences in the age of the donor patients and, most likely, the genetic variations 
among them, the actual variations between individual cell lines were minor. The results are 
presented as mean ± standard deviation. Quantitative reverse transcriptase polymerase chain 
reaction disclosed that cultured synovial fibroblasts contained mRNA coding for 1(IV) and 
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2(IV) chains, but also 4(IV) and 6(IV) chain mRNAs were present although at lower copy 
numbers, whereas 5(IV) and in particular 3(IV) were very low (Figure 6). Recombinant 
human TNF- and in particular rhIL-1 decreased (IV) chain mRNA copy numbers, but at 
the 0.1–10 ng/ml concentrations used, this effect did not show any clear dose dependency 
(see table 3).  
1(IV) 2(IV) 3(IV) 4(IV) 5(IV) 6(IV)
Control 100 100 100 100 100 100
IL-1, ng/ml 
0.1 81 70 49 40 71 55
1 68 64 62 45 68 45
10 77 65 59 36 54 29
TNF-, ng/ml 
0.1 74 74 85 91 88 102
1 79 73 100 109 83 51
10 67 67 109 83 72 111
Figure 6: Immunostaining showing different  chain. Labelling of collagen 1/2(IV) were 
strong while 5(IV) and 6(IV) were weak in trauma control synovial lining samples, while 
3(IV) or 4(IV) chains were not found. In comparison to rheumatoid synovial lining the 
labelling of all  chains were weak. Strong labelling of the vascular BM particularly the 
1/2(IV) chains in was strongly stained. Kidney tissue contains all the collagen -chains 
and therefore served as a positive (sample) control. For negative (staining) control non-
immune rabbit/mouse IgG was used instead of primary antibodies (magnification ×100). 
qPCR results  in synovial fibroblasts showed high quantity of  collagen  1/2(IV) mRNA 
copy numbers per 106-actin copies. The results are in logarithmic scale. 
Table 3: Mean values of the effect of 0.1–10 ng/ml recombinant human IL-1 and recombinant human TNF- on collagen
(IV)chain mRNA copy numbers in synovial fibroblasts compared with unstimulated synovial fibroblast controls.
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Double staining and confocal laser scanning microscopy of type IV collagen and 
CD68 or MMP-9 
As expected the synovial lining stained strongly for type IV collagen in the trauma 
control synovial membrane samples. Relatively few of the control synovial lining cells were 
CD68-positive macrophage-like type A lining cells 
(Panel C) or MMP-9 positive (Panel A). In contrast, 
the type IV collagen staining pattern in the 
rheumatoid synovial lining was weak and mottled 
(Panel B and D), and the rheumatoid synovial lining 
contained relatively numerous macrophage-like 
CD68-positive type A lining cells, which had 
arranged themselves into pseudostratified multiple 
layers (Panel D). Many of these rheumatoid synovial 
lining cells were also positive for MMP-9 (Panel B). 
Gelatin zymography of synovial fluid  
The presence of type IV collagenase or also known as human gelatinase (MMP-
2 and MMP-9) was identified of the in synovial fluid samples by using an efficient gelatine 
zymography technique. In trauma patients with 
only mild inflammation which had a synovial 
fluid leukocyte count of <0.5 x 109 cells/l, 
contained MMP-2 but only little or no MMP-9. In 
contrast, inflamed rheumatoid synovial fluid with 
a synovial fluid leukocyte counts >50 x 109 cells/l 
always contained MMP-9. The same synovial 
fluid samples contained also some constitutively 
expressed 72 kD gelatinase/ MMP-2 (Figure 8). 
Figure 7: Double IF staining of Collagen IV 
with CD68 and MMP-9 in trauma (control) and 
RA samples (magnification ×200).
Figure 8: Gelatine zymography showing collagenase 
IV activity. Lane 1 and 2 are synovial fluid samples 
from RA, while lane 3 and 4 are from mildly inflamed 
trauma patients. 
53
Laminin  chains in synovial lining 
Immunofluorescence staining of laminin 4 and laminin 5
Immunohistochemical staining revealed laminin 4 and 5 chains in the synovial 
lining in trauma samples and in the synovial lining-like layer of interface membrane samples 
retrieved during revision operations performed for 
aseptic loosening of total hip replacement implants 
(Figure 9, panels A,B,C and D). Laminin 4 was 
similarly labeled in OA samples (Figure 9, panel E), 
but 5 chain labelling was weaker in the synovial 
lining in OA samples than in trauma and revision 
hip samples (Figure 9, panel F). Reactions for both 
laminin 4 (Figure 9, panel G) and laminin 5
(Figure 9, panel H) chains were also weak in RA; 
they were found in most areas of the hypertrophic 
synovial lining, but there was a striking lack of 
laminin 5  (Figure  9,  panel  H,  between  the  arrow  
heads) in the presence of laminin 4 (Figure 9, 
panel G) in certain regions of the 
rheumatoid synovial lining. In laminin 
chain staining the presence of laminin 4
and laminin 5  chain  positive  BM  of  the  
blood vessels provided a useful internal positive staining control (Hallmann et al., 2005). 
Staining with irrelevant immunoglobulins of the same class and subtype, using the same 
concentrations as were used for immunolabeling, excluded false positive staining results (data 
not shown). 
Figure 9: IF staining for laminin 4 (red) and laminin 5
(green) in trauma (A and B), rTHR (C and D), OA (E and F) 
and RA (G and H). Arrow heads mark the synovial lining. 
Staining of both laminin chains in the vascular BM serves as 
an internal positive staining control. (magnification ×400. 
Negative staining control for laminin 4 (insert in panel G). 
54
Neutrophil elastase and cathepsin G in synovial membrane 
Neutrophil elastase (NE) and Cath G positive PMN were relatively infrequent in 
synovial membrane samples from trauma, revision and OA patients, except for intravascular 
neutrophils. Intravascular PMN in such samples usually stained strongly for both NE and 
Cath G (shown for NE in OA in Figure 10, panel A, for and for Cath G in panel B). 
In contrast, although not so easy to discern in hematoxylin-eosin stained routine 
slides, NE (Figure 10, 
panel  C)  and  Cath  G  
(Figure 10, panel D) 
immunoreactive PMN 
were quite frequent in RA 
synovial membrane 
samples compared to the 
other samples. In such 
samples  they  were  not  
only found in intravascular 
compartment, but were 
often seen attached to the 
vascular endothelium or 
transmigrating through it 
or found already in the 
perivascular and 
interstitial stroma as well as in the sublining and lining cell layers. Intravascular PMN stained 
strongly and this staining was confined to the cytoplasm of the cells (Figure 10, panels C and 
D, arrows). In contrast, many of the transmigrating PMN in the vascular wall and/or in the 
synovial lining stained more faintly and immunolabeled NE and Cath G was at the same time 
also seen outside the cell in the pericellular stroma (Figure 10, panels C and D, arrow heads).
Figure 10: NE (A) and cath G (B) in OA and RA (C and D, respectively). Staining 
is in OA mostly confined to the cell cytoplasm in intravascular neutrophils, 
whereas in RA some neutrophils below the synovial lining in perivascular matrix 
are in part degranulated so that extracellular proteinase aggregates can be seen in 
the synovial lining area (arrow heads, (magnification ×400). 
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Double staining of laminin 5 chain and neutrophil lactoferrin
Double IF disclosed lactoferrin-positive PMN attached to and transmigrating through 
the vascular BM. This was often seen in BM areas, where there seemed to be a break in 
laminin 5 staining (Figure 11, panels A and B). Transmigrating cells or perivascular cells 
just outside the blood vessel already in the interstitial tissue stained often relatively faintly 
and lactoferrin immunolabeling was also seen outside the cell in ECM (Figure 11, panel B). 
In the RA synovial stroma even small aggregates of PMN were often seen located between 
the sublining blood vessels and overlying synovial lining (Figure 11, panels C and D). 
Finally, in the synovial lining these cells converged to laminin 5 chain low expression 
regions, where they were located just below or within the synovial lining itself (Figure 11, 
panels E and F). 
Figure 11: Double IF staining of laminin 5 (green) and 
neutrophil Biomarker lactoferrin (red). Panel A shows a 
laminin 5 low expression area of the vascular BM with an 
attached neutrophil. B and C show neutrophils at different 
stages of (trans)migration in, at and outside the post-capillary 
venules. C shows that the staining of intravascular neutrophils 
is very strong and confined to the cell cytoplasm (thick arrow). 
In contrast, the extra-vascular neutrophils are in part 
degranulated and stain more faintly (arrow heads, C and D). 
Neutrophils seem to aggregate, migrate and transmigrate en 
masse, which is clearly seen in D. They seem to converge to 
laminin 5 low expression areas in the synovial lining (E, 
arrow), which is co-localized with transmigrating, lactoferrin-
immunoreactive and partly degranulated stream of neutrophils 
(F, arrows). Laminin 5 low expression regions in panel E were 
subjected to densitometry and panel G shows the densitogram, 
with two low expression regions. Inclination of the cutting 
angle in relation to the checkpoint region and the width of the 
rectangular area may contribute to some background laminin 
5 immunoreactivity (panel G). Negative staining control for 
laminin 5/lactoferrin double staining (H). (magnification. A,B 
are ×400 while C,D, E,F are ×200)
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Quantitative RT-PCR of laminin 4 and 5 chains in synovial fibroblasts 
Quantitative RT-PCR disclosed that cultured synovial fibroblasts contained mRNA 
coding for laminin 4 (1203 ± 211 mRNA copies per one million -actin mRNA copies) and 
laminin 5 chains (189 ± 126 copies per million -
actin mRNA copies), compared to the unstimulated 
synovial fibroblasts (Figure 12, dark gray bar C, 
normalized to 100). Recombinant human TNF-
(Figure 12) and IL-1 (data not shown) did not 
significantly decrease the laminin 4 chain 
expression, but laminin 5 chain mRNA copy 
numbers (per 106 -actin copies) were 
significantly decreased to about half of that of the controls by TNF- (p < 0.05, t-test). 
However, at the dose range used, 0.1–10 ng/ml, this effect did not show any clear dose 
dependency. 
Type IV collagen in human labial salivary gland  
Immunohistochemical staining of type IV collagen  chains 
Collagen type IV 1 and 2 chains showed continuous staining pattern in the ductal 
and alveolar domains of the tubuloalveolar BM of the labial salivary glands obtained from 
healthy controls. Staining patterns of collagen type IV 1 and 2 chains were similar in 
healthy  controls  and  patients  with  SS  (Figure  13,  panel  A  and  B).  Vascular  BM  were  also  
positive for collagen type IV 1 and 2 chains. 
Figure 12: qPCR analysis of laminin 4 and 5 chain 
mRNA copy numbers per 106 -actin copies in cultured 
human synovial fibroblasts from OA. C= control
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Collagen type IV 3 chain and collagen type IV 4 chain were not found in 
immunohistochemical staining in the tubuloalveolar BM of the labial salivary glands, except 
for some slight and focal staining in two of the 
samples  (not  shown).  Positive  staining  of  the  tubular  
BM of human kidney stained in parallel for collagen 
type IV 3 and 4 chains (see also Figure 13, panel H) 
provided a positive sample control confirming that the 
lack  of  staining  in  the  tubuloalveolar  BM  of  the  
salivary gland did not represent false negative 
staining. 
Collagen type IV 5 (Figure 13, panel 
C) and 6 chain (Figure 13, panel E) staining was 
continuous around the salivary ducts and also around 
the acini in healthy control glands although staining of 
the acinar BM tended to be weaker than that of the 
ductal BM. Staining pattern of these type IV collagen 
 chains in the tubuloalveolar BM of the labial 
salivary glands obtained from patients with SS was 
different  so  that  the  ductal  BM  staining  was  often  
disorganized and patchy and the acinar BM staining was often very weak or even absent 
(Figure 13, panels D and F). There were no apparent relationships between the type IV 
collagen 5 and 6 chains and the focus score. In particular, type IV collagen 5 and 6
chain staining pattern and intensity were similar in the tissue near and far away from the foci. 
Negative staining controls (Figure 13, panel G) were totally negative confirming the 
specificity of staining. Positive sample controls of human kidney sections stained in parallel 
with the labial salivary gland sections excluded false negative staining results (shown for type 
IV collagen 4 in Figure 13, panel H). 
Figure  13: Immunohistochemical staining of 
LSG showing type IV collagen  chains.
Kidney tissue served as a positive (sample) 
control. For negative (staining) control non-
immune rabbit/mouse IgG was used instead 
of primary antibodies (magnification ×400).
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Quantitative RT-PCR of the labial salivary glands and HSG cells  
Labial salivary gland obtained from patients with SS was compared with healthy 
control samples. Following collection these samples were analyzed using quantitative reverse 
transcriptase-PCR. The data obtained resulted 
in some useful observation (Figure 14). The 
mRNA molecules coding for all type IV 
collagen  chains were found in human labial 
salivary glands. Secondly, type IV collagen 1
and 2 chain mRNAs were found in clearly 
highest copy numbers, collagen type IV 5
and 6 chains were found in moderate mRNA copy numbers. The biopsies studied had focus 
scores ranging from 0.75 to 2.8 (1.8 ± 0.6). There were no apparent relationships between the 
type IV collagen 5 and 6 chain messenger RNA copy numbers and the focus score values. 
Collagen type IV 4 and in particular collagen type IV 3 chains were only present in 
relatively low mRNA copy numbers. Thirdly, there were no apparent differences in the type 
IV collagen  chain mRNA copy numbers in labial salivary glands between the healthy 
controls and patients with SS. 
Cultured human submandibular gland (HSG) cells grown with or without growth 
factor-depleted Matrigel was subjected to 
quantitative reverse transcriptase-PCR 
analysis and the results obtained are as 
shown in (Figure 15). The results 
demonstrated three conclusions based on the 
data obtained. As shown in the figure 14 the 
salivary gland epithelial cells transcribe all 
type IV collagen  genes into the 
corresponding mRNA. The copy numbers of mRNA molecules coding for collagen type IV 
1 and 2 chains were high, those coding for collagen type IV 4-6 chains were intermediate 
and those coding for collagen type IV 3 chains were low. Lastly, these experiments showed 
that both the HSG cells with the intercalated duct cell phenotype (cultured without Matrigel) 
Figure  15: qPCR analysis of HSG cells grown in the 
presence or absence of matrigel showing mRNA coding 
for type IV collagen  chains.
Figure  14: qPCR analysis of LSG cells control and 
from  patients with Sjögrens syndrome showing mRNA 
coding for type IV collagen  chains.
59
and the HSG cells with the acinar cell phenotype (cultured with Matrigel) synthesize type IV 
collagen  chain mRNA.  
Immunohistochemical staining of vWF 
In haematoxylin eosin stained slides pre-capillary arterioles were relatively 
large and round vessels about 30 m in diameter but with a wide size range from 300 m
down to 10 m and their endothelium was surrounded by smooth muscle cell medial layer 
and pericyte adventitial layer. Capillaries were small and slender vessels 5-10 m in 
diameter, in which the endothelium was not supported by medial or adventitial layers, 
whereas post-capillary venules were voluminous vessels 10-50 m diameter with varying 
shapes supported by a few muscle cells and by pericytes. 
Von Willebrand factor was in healthy labial salivary glands located in the 
endothelium of 
arterioles, capillaries 
and post-capillary 
venules (Figure 16, 
panels A, B and C).  
In SS vWF staining was focally and segmentally weak and at these affected 
sites associated with staining of the perivascular connective tissue matrix (Figure 16, panels 
D-F). It was possible to see release, diffusion and binding of vWF from endothelium to 
perivascular and interstitial matrix (Figure 17, panel A). Negative staining controls, which 
were used to confirm the specificity of vWF staining, were negative (Figure 17, panel B). 
Immunostained labial salivary gland tissue sections left without counterstaining were 
Figure 16: Immunohistochemical staining of vWF in control and patients with Sjögrens 
syndrome (magnification ×400). Healthy LSG A,B,C; Sjögren’s syndrome C,D,F
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observed under a light microscope and analyzed using a semi–automatic VIDAS image 
analysis system. The average areas of vWF delineated capillary blood vessels were 5068.0, 
4220.3 and 
3785.0 μm2 per 
mm2
parenchymal 
acinar tissue in 
primary SS, 
secondary SS 
and healthy controls, 
respectively, with standard 
errors of mean of 673.1, 763.4 and 383.0, respectively. Arterioles and post-capillary venules 
were excluded from the analysis. The numbers of vWF positive capillary blood vessel 
profiles are shown in table 1 per mm2 parenchymal acinar tissue.
Figure 17: Close up view of Immunohistochemically stained vWF in control 
and patients with Sjögrens syndrome, A (magnification ×600). Negative 
staining control, B.
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DISCUSSION
Basement membrane and synovial lining 
asement membrane (BM) is in many respects important due to its role in the 
maintenance of healthy tissues. It imparts compartmentalization to tissue 
structures, provides terra firma for cells and plays a key role in providing 
important matrix-cell signalling directing the cells in differentiation, maintenance and 
remodelling. In many locations in particular in the renal glomerulus, the BM functions as a 
molecular sieve (Hudson et al., 1993).   
The normal synovial lining lacks a true BM but contains instead intercellular 
cementing substance comprised of the same set of molecules characterizing BM, suggesting 
that this network of the intercellular matrix contributes to the organization and regulation of 
the synovial lining. This type of organization of macrophages- and fibroblast-like cells in 
intercellular matrix to a lining cell layer seems unique. It probably reflects the specialized 
functional role of the synovial lining in diarthroidal synovial joints, tendon sheets and bursae. 
Fluid in these cavities is mostly ultra filtrate of plasma with hyaluronan, lubricants and other 
locally synthesized additives to promote hydration, lubrication etc. Macrophage-like type A 
lining cells may play a role in the clearance if eventual cartilage or other tissue fragments, 
apoptic synovial fluid neutrophils and other cells and probably participate in the remodelling 
and  renewal  of  this  layer  (Rinaldi  et  al.,  2001).  In  chronic  synovitis  a  considerable  
remodelling is observed in synovial lining. In RA synovial lining undergoes villous 
hypertrophy leading to an increase of its surface area (villi) and depth (multiple 
pseudostratified layers). This allows an immense increase in the leukocyte, in particular 
neutrophil, traffic from the synovial membrane microcirculation to synovial fluid, but also 
effective removal of the apoptotic neutrophils and other apoptotic cell rests. The synovial 
lining cells are potential effectors in the destructive arthritic process and have been shown to 
synthesize inflammatory cytokines (Schneider et al., 1994) and proteolytic enzymes 
(Konttinen et al., 2000a; Okada et al., 1990).  
B
62
The fibroblast-like type B and macrophages-like type A synovial lining cells probably 
produce the intercellular matrix. In between these two cell layers it is possible to find most, if 
not all, components of the BM (Revell et al., 1995). As mentioned earlier, the two major 
components of the BM are the type IV collagen network and the laminin network. Integrins at 
various combinations of their   and  chains form most of the cellular receptors to type IV 
collagen and laminin molecules. The laminin chain composition of this intercellular lining 
matrix has been earlier described by Konttinen and co-workers (Konttinen et al., 1999), 
which among other things showed the lack of integrin 6 and integrin 4 chains, which are 
crucial hemidesmosomal components in their attachment to the underlying BM and this 
finding demonstrates that in spite of its histological lining-like appearance, synovial lining is 
not analogous to epithelia attaching to an underlying BM via hemidesmosomes. As a 
continuation to the former study we undertook this study to identify also  chain composition 
of type IV collagen in synovial lining. Maybe because the synovial membrane needs to 
provide nutrition to hyaline articular cartilage under very special circumstances, the synovial 
intima does not contain a BM similar to that which surrounds blood vessels or underlies 
human skin. Synovial intima or lining cell layer forms a sheet-like and compact-looking 
structure composed of fibroblast-like type B and macrophage-like type A lining cells which 
needs to have mechanical strength and flexibility (Stevens et al., 1990). Although it is a BM-
like  structure,  it  is  not  an  epithelium  or  endothelium  and  does  not  contain  a  basal  and  
coherent BM but is still enforced by an intercellular type IV collagen network,  chain 
composition of which was disclosed in the present study.  
This structure therefore qualifies to be called a special extracellular lining matrix and 
is of particular interest due to its role as a leukocyte barrier and for cartilage nutrition. This 
study disclosed the presence of 1/2(IV), 5(IV) and 6(IV) chains in control synovial lining. 
Cultured synovial fibroblasts were also analyzed to confirm this findings by using 
quantitative RT-PCR although this sensitive method also disclosed traces of  messenger RNA 
coding 3(IV) and even 4(IV) chains. It was apparent, the mRNA level and/or the translation 
to the corresponding 3(IV) or 4(IV) protein chains was so low (or perhaps even absent) that 
it could not be seen in IF staining experiments. It was shown that the major type IV collagen 
 chains in normal synovial lining are the 1(IV) and 2(IV).  This  is  compatible  with  the  
observation  that  they  form  the  components  of  the  major  form  of  the  three  now  known  
collagen type IV heterotrimers, namely the classical 2, the other two forms with a more 
restrictive tissue distribution being 
5 and 6 (Khoshnoodi et al., 2008). The 
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antibody used for staining of the major -chains 1(IV) and 2(IV) did not differentiate 
between them, i.e. it recognized them both. The presence of these major  chains was further 
confirmed by qRT-PCR. Both 1(IV)  and  2(IV) messenger RNAs were found in cultured 
synovial fibroblasts indicating that both are present in synovial lining and are at least to an 
extent locally produced by type B synoviocytes. 
The rheumatoid synovial lining differed from the normal synovial lining. It contained 
very little or even lacked 1/2(IV), 5(IV) and 6(IV) chains in staining or, alternatively, their 
expression was below the detection threshold of the IF method used. Thus, the type IV 
collagen  chain proteins are very low in rheumatoid synovial lining indicating that binding 
of type A and B to the lining cell layer is probably relatively loose in the hyperplastic 
rheumatoid synovial lining compared to the healthy synovial lining. This may allow their 
interfacial movement in relation to each other upon joint extension, flexion and more 
complicated motility patterns. This probably results in the detachment of synovial lining cells 
as  was  can  be  seen  in  the  cytological  analysis  of  rheumatoid  synovial  fluid  (Stebulis  et  al.,  
2005). This loosening of the intercellular matrix in RA might in part contribute to synovial 
effusions, which are characteristically found in this and other inflammatory joint diseases. In 
the normal knee joint the fluid volume has been estimated to be 6.7 ± 2.3 ml, compared to 
13.6 ± 7.4 ml in mild OA and to 24.2 ± 16.3 ml in activated OA (Heilmann et al., 1996), but 
often much higher in RA (Yunus, 1981).  
To gain insight in non-RA inflammatory disease synovial membrane from OA and 
synovial membrane-like interface tissue, which represents foreign body synovitis around 
loosening total hip replacement implants, were studied. This approach helps to understand if 
these changes are specific for RA. A relatively similar result was observed in these two 
conditions as was seen in traumatic synovial membrane. However, it is still likely that the 
disappearance of the interstitial type IV collagen in RA is not a disease specific feature per se
but results from chronic and active inflammation. 
Our findings direct us towards some conclusions for the diminished synovial lining 
type IV collagen  chains in RA. The proportion of synovial lining macrophage-like type A 
cells marked by CD68 which is a monocyte/macrophage marker is greatly increased in RA. 
This has been described before (Athanasou et al., 1988) and reflects the role of the villous 
and hyperplastic lining in the management of apoptotic synovial fluid neutrophils in RA. For 
example, in a knee joint containing 50 ml synovial fluid with 50 x 109/l neutrophils, 1.25 x 
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109 apoptotic neutrophils have to be managed during one day if the neutrophils are expected 
to have a two-day life span after they have left the intravascular compartment and entered the 
synovial fluid. The macrophage-like type A lining cells do not produce type IV collagen. In 
the synovial lining it is produced by fibroblast-like type B lining cells. Therefore, the 
hyperplastic synovial lining, which contains an increased proportion of macrophage-like type 
A lining cells, contains relatively few type IV collagen producer cells. 
A  second  reason  for  the  diminished  type  IV  collagen   chain  expression  in  the  
rheumatoid synovial lining might relate to inflammatory stimulation of the rheumatoid 
synovial lining fibroblast-like type B cells. In pursuit of this hypothesis, rheumatoid synovial 
fibroblasts were stimulated with pro-inflammatory doses of IL-1 or TNF- which resulted in 
a decreased type IV collagen  chain mRNA levels in the stimulated synovial fibroblasts. 
Physiologically relevant values were used by investigating a range of the concentrations of 
these cytokines. Only IL-1 stimulations disclosed a tendency to dose-response, whereas 
TNF- did not. These results indicate that both of these pro-inflammatory cytokines decrease 
type IV collagen  chain synthesis in rheumatoid synovial fibroblasts. In vivo, they are likely 
to act in concert, and together with other locally produced pro-inflammatory cytokines. Such 
combined inhibition by pro-inflammatory cytokines may also contribute to the diminished 
local synthesis of type IV collagen in synovial lining.  
An increased local and/or extrinsic type IV collagenase activity could be a third 
possible reason for the diminished type IV collagen expression in the rheumatoid synovial 
lining. In rheumatoid synovial lining MMP-9 (92 kD type IV collagenase, gelatinase B) was 
greatly increased, particularly in the macrophage-like type A lining cells. Activation of the 
rheumatoid synovial lining is indicated by an increased MMP-9 expression, which is 
inducible by pro-inflammatory factors and MMP-9 positivity indicates an activated state of 
the cell. In addition, inflammatory rheumatoid synovial fluid contained, according to 
zymographies, increased MMP-9 activity. Neutrophils form the major source of synovial 
fluid MMP-9. Because the healthy synovial fluid contains < 0.2 x 109 leukocytes per litre and 
< 25% of them are neutrophils (Altman, 2007), it is likely that the amount of MMP-9 would 
be lower in healthy synovial fluid than in our mildly inflammatory synovial fluid samples 
(although it was also there below the detection limit of the zymography). The locally 
produced MMP-9 as well as the MMP-9 released by neutrophils traversing the lining or 
residing in the synovial fluid, may contribute to local degradation of type IV collagen and, 
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thus, to the diminished expression of type IV collagen  chains in the rheumatoid synovial 
lining.  
Earlier pioneering findings have demonstrated the presence of type IV collagen in 
synovial lining (Pollock et al., 1990; Schumacher, 1975), which was confirmed by the present 
work  and  extended  to  an  analysis  of  the   chain  composition  of  this  type  IV  collagen  
network. Type IV collagen  chain expression was greatly diminished in rheumatoid synovial 
lining, probably due to multifactorial reasons, which all contribute to the same end outcome 
and include increased proportion of type IV collagen non-producers (macrophage-like type A 
lining cells), increased local degradation by MMP-2 and MMP-9 locally synthesized and/or 
released (by synovial lining and fluid cells) and diminished local type IV collagen production 
as a result of inflammatory functio laesa caused by TNF- and IL-1.
Neutrophil migration through laminin 5 low expression regions  
The BM is structurally rugged to provide the adherent cells with structural support 
and provides a partial physical barrier by restricting the movement of the biological 
molecules. Usually the pore size of the BM is approximately 50 nm, permitting the 
bidirectional movement of only small molecules (Abrams et al., 2000a; Abrams et al., 2000b; 
Kalluri, 2003). Normally, certain cells like neutrophils are able to trespass this barrier 
relatively freely and rapidly migrate through these BM by interaction with the cells 
underlying the BM mainly via integrin receptors (Huber and Weiss, 1989; Ley et al., 2007). 
The RA synovial fluid typically contains high numbers of PMNs. In RA synovial 
fluid leukocytes reach often up to 5-50 x 109/l and most of these leukocytes are neutrophils 
(Harris, 1990). Furthermore, although neutrophils mature in the bone marrow for 10-14 days, 
they only circulate for 6-12 hours and after transmigration into tissues and body fluids live 
for 1-3 additional days before undergoing apoptosis (Bainton, 1975). This means that the 
neutrophil efflux to and turnover in synovial fluid is enormous. Generally migrating cells are 
unable to efficiently pass through pores with diameter < 2m in size. Our results suggest that 
neutrophils pass through the synovial lining using laminin 5 low expression regions. Such 
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gateway regions were found in the synovial lining and double staining disclosed that exactly 
these regions contained transmigrating neutrophils. Transmigrating neutrophils were 
identified by their lactoferrin content. Lactoferrin is a neutrophil marker and is formed during 
the myelocyte stage of neutrophil development. It forms an important component of the 
granules specific for neutrophils, therefore called specific granules (or secondary granules 
because they form first after the primary or azurophil granules, which form already during the 
promyelocyte stage and are, in contrast to the neutrophil specific granules, also found in other 
myeloid cells, like monocyte/macrophages). 
In RA synovial fibroblasts, TNF- decreased significantly laminin 5 chain mRNA 
levels and probably also its synthesis. IL-1 had a similar effect although this was not 
statistically significant. A combined effect may significantly decrease the concentration of the 
interstitial laminin 5 in the hypertrophic rheumatoid synovial lining. Interestingly, these 
same cytokines induce chemokines, including IL-8, epithelial neutrophil activating peptide-
78, monocyte chemoattractant protein-1 and macrophage inflammatory protein-1. In 
particular, the best recognized biological activities of IL-8 centre around its effects on 
neutrophils. The stimulated synovial cells release IL-8 which thereby increases in 
concentration in rheumatoid synovial tissue and fluid (Brennan et al., 1990; Golds et al., 
1989; Koch et al., 1991; Koch et al., 2001; Seitz et al., 1991). The pannus–cartilage junction 
is yet another region where IL-8 has been detected. The chemotactic activity of synovial fluid 
for neutrophils was inhibited by 40% when IL-8 was neutralized by an appropriate antibody. 
This indicates that IL-8 in rheumatoid synovial fluid is functional (Koch et al., 2001). More 
chemotactic stimuli are produced by complement degradation products (Low and Moore, 
2005; Zvaifler, 1974) produced by immune complex-mediated complement activation. 
Notably, RA has been considered to be an extravascular, intra-articular immune complex 
disease, driven by IgG and rheumatoid factor complexes and complement activation. This 
paradigm, so nicely formulated by Professor Nathan J. Zvaifler, still holds true today 
(Edwards and Hallett, 1997; Zvaifler, 1974). Our immunohistopathological findings were in 
agreement with an effective and massive neutrophil migration from the circulatory 
compartment to the synovial fluid using laminin 5 low expression regions as the trans-lining 
neutrophil gateways. 
Neutrophil elastase (NE) and Cath G belong to neutrophil serine proteinases. They are 
active proteinases stored in the neutrophil granules and they can be secreted to the 
67
extracellular space upon stimulation. NE is considered as an important in vivo activators of 
pro-MMPs, including the inducible 92 kD type IV collagenase or MMP-9 but not the 
constitutively expressed pro-form of 72 kD type IV collagenase or MMP-2 (Nagase, 1997). 
The neutrophil Fc receptors cross-linked by immune complexes lead to full neutrophil 
activation (Willis et al., 1988). Consequently, immune complex-activated neutrophils 
discharge large quantities of toxic products, overwhelming the anti-proteinase shields of 
synovial fluid (Abbink et al., 1993; Ossanna et al., 1986). This neutrophil 
activation/degranulation has been considered to be important for destruction of hyaline 
articular cartilage as pro-infammatory cytokines capable of prolonging neutrophil survival are 
detectable in the RA synovial fluid (Chatham et al., 1993; Ugai et al., 1983; Weiss, 1989). 
We speculate that the migrating neutrophils generate by a localized and timely degranulation 
and by a concerted serine and MMP action gateway regions so that neutrophils can 
successfully complete their migratory mission, quite like they do in transendothelial 
migration (Wang et al., 2006b). Also, this is the first time the presence of laminin 4 chain is 
shown in the synovial lining layer. As suggested by Hallmann (Hallmann et al., 2005), it is 
possible that in the BM containing laminin 4 isoform but lacking laminin 5 isoform, the 
ability of the truncated “tau-cross” laminin 4 alone to self assemble and to be incorporated 
into the intercellular matrix may be compromised. Due to the NH2-terminal truncation of 
laminin 4 chain this result in a “looser” network making the penetration of migrating 
neutrophils easier. Our findings and the proposed theory provide substantial and logical 
insight to the simple but effective mechanism by which neutrophils could migrate across the 
synovial lining into the synovial fluid. 
Type IV collagen and vWF in the labial salivary gland from Sjögren’s 
syndrome  
Collagen type IV  chain composition in the tubuloacinar BM of the human labial 
salivary glands has not been reported before. Our hypothesis was that there might be some 
ductal and acinar compartment specific differences in type IV collagen  chain composition, 
which might affect the transdifferentiation of the intercalated duct progenitor cell into 
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secretory acinar cells in the acini. The presence of a positive stimulatory or lack of negative 
repressive factor could drive the transdifferentiation of an intercalated duct epithelial 
progenitor cell into a secretory acinar cell in healthy glands. No such acinar compartment 
specific differences in type IV collagen  chain composition were found. This suggests that 
type IV collagen  chain do not guide the differentiation of the progenitors to terminally 
differentiated acinar cells. This is in contrast to the presence laminin 1 chain only found in 
acini (and not present in the ducts), which according to the known combinatorial rules for 
trimeric laminins forms in acini part of Ln-111 (earlier laminin-1) (Aumailley et al., 2005). 
Not only was Ln-111 topologically restricted to the acinar compartment in healthy glands, but 
it was also weak or lacking in the acinar compartment in the labial salivary glands in patients 
with SS (Laine et al., 2004). This is in concert with the in vitro HSG-Matrigel culture system, 
in which cell culture model laminin 1 chain has been shown to be essential to the 
intercalated duct cell-to-acinar cell differentiation (Crema et al., 2006; Hoffman et al., 1996; 
Jung et al., 2000; Royce et al., 1993; Vag et al., 2007; Zheng et al., 1998). Type IV collagen 
 chains do not seem to provide a similar differentiation signals. Although several microarray 
experiments (Gottenberg et al., 2006; Hjelmervik et al., 2005; Killedar et al., 2006) and 
proteomic (Hu et al., 2007; Ryu et al., 2006) studies have been done on the salivary gland and 
whole saliva from patients with SS, the profile of collagen type IV  chains was not studied 
in any of them. 
The second aim of the paper related intimately to its first aim. We tried to clarify if 
the ductal and acinar tubuloacinar BM are different in healthy controls and in patients with 
SS. In particular, it would have been interesting if some acinar compartment specific type IV 
collagen  chain eventually able to provide a positive differentiation signal would have been 
found in healthy control glands but would have lacked in SS; or conversely, if some 
potentially repressive signal not found in healthy glands would have been present in acini in 
SS. Also this part of the hypothesis was refuted as no such type IV collagen  chain specific 
difference were found between healthy controls and patients with SS. 
Although our two-part working hypothesis was disapproved, some interesting 
findings and tentative conclusions emerged. Watery saliva derives from plasma as part of the 
salivation reflex, whereas the salivary mucins are produced by and stored in the acinar cells 
(Berne MR, 2004). Thus, production of saliva subjects the acini and acinar BM to 
considerable stretching by watery saliva and hydrophilic salivary mucins. Upon stimulation 
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of the salivation reflex by mastication (mechanical stimulation), food (gustatory stimuli), 
smell of the food (olfactory stimuli) and/or thought of the food (mental stimuli), the 
myoepithelial  cells  surrounding the acini contract  to empty the acinar cells and to expel the 
primary saliva produced to the salivary ducts. This subjects the acini and acinar BM to a 
considerable constriction and diminution of the volume; whereas the salivary ducts and their 
tubular BM are subjected to a considerable stretching as saliva passes through the ductal 
system towards the mucous membrane. Interestingly, type IV collagen 5 and 6 chains 
have been reported to be present in the BM of aortic smooth muscle cells (Seki et al., 1998), 
which are subjected to cyclic stretching as a result of pulse and blood pressure waves. BM of 
the smooth muscle cells in the wall of other organs, like esophagus, stomach and urinary 
bladder, subjected to alternating and sometimes relatively large and sudden dilations and/or 
constrictions, also contain type IV collagen 5 and 6 chains and probably the 6 timer 
(Kiyofuji et al., 2002; Seki et al., 1998). It is therefore concluded that type IV collagen 5
and 6 chains may also in the salivary glands impart the tubuloacinar BM of healthy glands 
with elasticity allowing stretching and recoil of acinar and ductal salivary BM. Relatively 
weak type IV collagen 5 and 6 chain expression in diseased glands may compromise this 
quality in SS. However, this structural abnormality may be secondary to the diminished 
salivary flow (disuse atrophy) and/or increased local synthesis of matrix metalloproteinases 
able to degrade type IV collagen in the BM (Azuma et al., 1997; Goicovich et al., 2003; 
Hanemaaijer et al., 1998; Konttinen et al., 1994; Seki et al., 1998). 
Type IV collagen 1 and 2 chains were present in highest mRNA copy numbers and 
their staining was strong and solid. This indicates that these two type IV collagen  chains 
form the backbone of the structurally supporting tubuloacinar BM of the salivary glands. 
They might also play some important functional role, like prevention of anoikis, a special 
form of apoptosis due to loss of cell-matrix contact (Manganelli and Fietta, 2003). These two 
 chains are considered as universal BM components and exist throughout the body (Tanjore 
and Kalluri, 2006). In contrast, type IV collagen 3 and 4 chains are more restricted and 
tissue specific in their distribution and are found for example in the fetal kidney glomeruli 
and also in adult kidneys, but restricted to BM of glomerular Bowman’s capsule and some of 
the distal tubules and collecting ducts (Lohi et al., 1997). These general observations are in 
line with our present findings on the presence and distribution of these  chains in human 
labial salivary glands. 
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Von Willebrand Factor in capillary blood vessels of labial salivary gland  
Von Willebrand factor is specifically synthesised by vascular endothelial cells and 
megakaryocytes and stored mostly in Weibel-Palade bodies and to a smaller extent in the -
granules of megakaryocytes and platelets, which constitutes 15-20 % of the total vWF. VWF 
is not synthesized and/or stored by any other cells. The secretion of vWF follows three 
routes: 1) the constitutive secretion is a continuous process of release and requires no cellular 
stimulation; 2) the regulated release of vWF occurs from the Weibel-Palade bodies upon 
cellular stimulation, in response to secretagogues, or upon vascular endothelial cell damage; 
3) a third pathway involves both of the above so that processed vWF from the Golgi complex 
is targeted to storage granules as in regulated secretion but is continuously secreted from this 
storage pool without provocation (constitutive-like secretion or basal secretion) (Johnsen and 
Lopez, 2008). In immunohistopathology vWF is therefore often used as a specific 
immunohistochemical endothelial cell marker. Its location relates to its hemostasis-specific 
dual function. One of these functions is constitutive binding to and stabilization of 
coagulation factor VIII (haemophilia A factor). Therefore, vWF is often also called factor 
VIII-related antigen, but this name only relates to its constitutively secreted oligomeric form; 
dimeric  vWF  has  a  molecular  weight  of  approximately  540  kD.  Some  of  the  mutations  of  
vWF lead to an inability to bind to factor VIII, which is then destabilized and has a short half 
life, which leads to haemophilia A-like symptoms, like intra-articular and major internal 
bleedings. High molecular weight forms of vWF, containing maximally up to 50-100 dimeric 
protomers (Ruggeri, 1999), are in the endothelial cells stored in rod-shaped Weibel-Palade 
bodies, which form the ultramorphological markers for endothelial cells in transmission 
electron microscopic studies, again emphasizing its endothelial cell specificity. 
Immunohistochemical staining of vWF showed a surprisingly dense microvasculature in the 
healthy human LSGs by disclosing vWF immunoreactive endothelial lining in the rounded 
arterioles with well developed medial smooth muscle cell layer, tiny capillaries consisting of 
endothelial cells organized by capillary basement membranes without medial or adventitial 
cell layers, and much larger, thin walled post-capillary venules with relatively large vascular 
lumina of variable shapes. This easy identification of different blood vessels was possible 
based on the strong vWF staining of the vascular endothelial cells, with practically no non-
specific cellular or matrix background staining.  
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VWF occurs in Weibel-Palade bodies also in polymeric, high molecular weight 
form that may be 25,000-50,000 kD. This form of vWF is not constitutively released, but is 
only released upon activation and, in particular, upon damage of vascular endothelial cells. It 
does not stabilize factor VIII but contributes to haemostasis in a different way, by acting as 
an inter-adhesive glycoprotein. It forms bridges between subendothelial perivascular 
collagens (collagen-binding domains) and blood platelets (platelet glycoprotein-binding 
domain) promoting platelet adhesion to sites of vascular damage. Furthermore, polyvalent 
vWF binds platelets to other platelets, cross-linking platelets via their vWF receptors utilizing 
gp Ib-IX-V and gp IIb-IIIa, contributing to local platelet aggregation. This vWF function is 
particularly important under high shear rate conditions in the arteriolar resistance blood 
vessels, but also in microvasculature in general. Damage-induced release of high molecular 
weight polyvalent vWF has, apart from its platelet adhesion and aggregation promoting 
properties, two other consequences of relevance in this context (eponis et al., 1996b). 
Release of vWF from endothelial cells causes weakening of the endothelial cell staining. This 
is caused by the diminished number of antibody binding immunoreactive vWF epitopes in 
damaged cells, which have released much of their vWF stores. Second, release and binding of 
vWF to the perivascular connective tissue leads to perivascular vWF deposits, due to high 
avidity polyvalent binding. Naturally some of the vWF is released into the circulation, which 
was not studied in this work but has been reported elsewhere (Blann et al., 1992). These two 
reciprocal phenomena were not seen in the microvasculature in healthy control LSGs, but 
were often observed as focal phenomena in arterioles, capillaries and venules in SS. This 
indicates that focal sialadenitis in SS is caused by or leads to microvascular injury, well in 
accordance with the hypothesis presented in the introduction. Such local vascular damage is 
likely to activate platelets to form white platelet microthrombi and to initiate coagulation 
leading to impaired microcirculation, which might impair the formation of primary saliva in 
the peri-acinar capillary network.  
We expected to observe vascular damage to lead to destruction and loss of 
capillary blood vessels in LSGs in SS because this would have helped to explain the exocrine 
failure and quantitative (and qualitative) impairment of saliva so typical to this syndrome. In 
spite of relatively extensive microvascular damage, salivary gland capillaries were not 
significantly decreased in numbers in SS compared to healthy controls. On the contrary, 
capillary blood vessel density showed a slight trend to increment, perhaps representing an 
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effort to compensate via angiogenesis for the impaired and dysregulated peri-acinar capillary 
flow caused by microvascular damage. 
To extend the present study, future studies should address functional 
characteristics of salivary gland microcirculation because impaired relaxation of the 
precapillary sphincter and dysregulated coordination of the vascular functions with acinar and 
myoepithelial cells functions creating the transacinar osmotic and hydrostatic gradients 
necessary for salivary flow (Konttinen YT, in press) might greatly contribute to impaired 
salivary flow in SS. It has long been disputed whether or not SS is associated with autonomic 
neuropathy, but such studies have mostly focused on cardiovascular tests (Andonopoulos et 
al., 1998; Barendregt et al., 1999; Cai et al., 2008; Kovacs et al., 2004; Mandl et al., 2007; 
Niemela et al., 2003; Tumiati et al., 2000) although autonomic dysfunction in SS might 
particularly affect the exocrine glandular function, the study of which might provide more 
uniform data on its eventual presence or absence. 
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CONCLUSION AND FUTURE PROSPECTS
The major components of the BM are type IV collagen network and laminin network. 
VWF binds to collagen and captures platelets from rapidly flowing blood at sites of vessel 
wall injury. It serves as a carrier for coagulation factor VIII, which it delivers to the sites of 
coagulation enzyme complex assembly. 
The aim of this study was twofold- Firstly, to determine the composition of the type 
IV collagen in the synovial lining of the RA patient and in the tubuloacinar BM in the labial 
salivary gland of the SS patient. Both these were compared with sample controls.  In case of 
RA the patient controls were from OA and trauma patients while in SS the negative sample 
controls were obtained from patients who were suspected but did not have SS. Secondly, this 
thesis aimed to investigate even deeper investigating the role of the BM component laminin 
4 and laminin 5 in the migration of neutrophils from the blood vessels thorough the 
synovial lining layer into synovial fluid and the presence of vWF in the microvasculature of 
labial salivary gland in SS. Since primary saliva is produced as a result of transudation from 
periacinar capillary blood vessels we hypothesize that blood vessels would be damaged and 
capillaries would be low in numbers in salivary glands contributing in a characteristic 
hyposalivation in SS. 
This twofold approach allows us to intuitively understand the intricate relation 
between the ECM components and the immunopathological changes that occur during the 
pathogenesis of these inflammatory rheumatic disease processes. Also notably this study 
highlights the importance of maintaining a healthy ECM to prevent the progression or 
possibly allow reversal of the disease to a considerable level. Furthermore, it can be 
speculated that a healthy BM could quarantine the inflamed region or in case of cancer cells 
barricade the movement of malignant cells thereby preventing further spread to the 
surrounding areas. This understanding can be further applied to design appropriate drugs 
which act specifically to maintain a proper BM/BM like intercellular matrix composition 
especially in diseases that have the tendency to spread to adjacent or far off regions. The 
current attention directed towards this approach is inadequate and calls for further molecular 
understanding alongside further pharmacological development. 
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